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A B S T R A C T
Background
This is an update of the original Cochrane review, last published in 2009 (Huertas-Ceballos 2009). Recurrent abdominal pain (RAP),
including children with irritable bowel syndrome, is a common problem affecting between 4% and 25% of school-aged children. For
the majority of such children, no organic cause for their pain can be found on physical examination or investigation. Many dietary
inventions have been suggested to improve the symptoms of RAP. These may involve either excluding ingredients from the diet or
adding supplements such as fibre or probiotics.
Objectives
To examine the effectiveness of dietary interventions in improving pain in children of school age with RAP.
Search methods
We searched CENTRAL, Ovid MEDLINE, Embase, eight other databases, and two trials registers, together with reference checking,
citation searching and contact with study authors, in June 2016.
Selection criteria
Randomised controlled trials (RCTs) comparing dietary interventions with placebo or no treatment in children aged five to 18 years
with RAP or an abdominal pain-related, functional gastrointestinal disorder, as defined by the Rome III criteria (Rasquin 2006).
Data collection and analysis
Weused standard methodological procedures expected by Cochrane.We grouped dietary interventions together by category for analysis.
We contacted study authors to ask for missing information and clarification, when needed. We assessed the quality of the evidence for
each outcome using the GRADE approach.
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Main results
We included 19 RCTs, reported in 27 papers with a total of 1453 participants. Fifteen of these studies were not included in the previous
review. All 19 RCTs had follow-up ranging from one to five months. Participants were aged between four and 18 years from eight
different countries and were recruited largely from paediatric gastroenterology clinics. The mean age at recruitment ranged from 6.3
years to 13.1 years. Girls outnumbered boys in most trials. Fourteen trials recruited children with a diagnosis under the broad umbrella
of RAP or functional gastrointestinal disorders; five trials specifically recruited only children with irritable bowel syndrome. The studies
fell into four categories: trials of probiotic-based interventions (13 studies), trials of fibre-based interventions (four studies), trials of
low FODMAP (fermentable oligosaccharides, disaccharides, monosaccharides and polyols) diets (one study), and trials of fructose-
restricted diets (one study).
We found that children treated with probiotics reported a greater reduction in pain frequency at zero to three months postintervention
than those given placebo (standardised mean difference (SMD) -0.55, 95% confidence interval (CI) -0.98 to -0.12; 6 trials; 523
children). There was also a decrease in pain intensity in the intervention group at the same time point (SMD -0.50, 95% CI -0.85
to -0.15; 7 studies; 575 children). However, we judged the evidence for these outcomes to be of low quality using GRADE due to an
unclear risk of bias from incomplete outcome data and significant heterogeneity.
We found that children treated with probiotics were more likely to experience improvement in pain at zero to three months postin-
tervention than those given placebo (odds ratio (OR) 1.63, 95% CI 1.07 to 2.47; 7 studies; 722 children). The estimated number
needed to treat for an additional beneficial outcome (NNTB) was eight, meaning that eight children would need to receive probiotics
for one to experience improvement in pain in this timescale. We judged the evidence for this outcome to be of moderate quality due
to significant heterogeneity.
Childrenwith a symptomprofile defined as irritable bowel syndrome treatedwith probiotics weremore likely to experience improvement
in pain at zero to three months postintervention than those given placebo (OR 3.01, 95% CI 1.77 to 5.13; 4 studies; 344 children).
Children treated with probiotics were more likely to experience improvement in pain at three to six months postintervention compared
to those receiving placebo (OR 1.94, 95% CI 1.10 to 3.43; 2 studies; 224 children). We judged the evidence for these two outcomes
to be of moderate quality due to small numbers of participants included in the studies.
We found that children treated with fibre-based interventions were not more likely to experience an improvement in pain at zero to
three months postintervention than children given placebo (OR 1.83, 95% CI 0.92 to 3.65; 2 studies; 136 children). There was also no
reduction in pain intensity compared to placebo at the same time point (SMD -1.24, 95% CI -3.41 to 0.94; 2 studies; 135 children).
We judged the evidence for these outcomes to be of low quality due to an unclear risk of bias, imprecision, and significant heterogeneity.
We found only one study of low FODMAP diets and only one trial of fructose-restricted diets, meaning no pooled analyses were
possible.
We were unable to perform any meta-analyses for the secondary outcomes of school performance, social or psychological functioning,
or quality of daily life, as not enough studies included these outcomes or used comparable measures to assess them.
With the exception of one study, all studies reported monitoring children for adverse events; no major adverse events were reported.
Authors’ conclusions
Overall, we found moderate- to low-quality evidence suggesting that probiotics may be effective in improving pain in children with
RAP. Clinicians may therefore consider probiotic interventions as part of a holistic management strategy. However, further trials are
needed to examine longer-term outcomes and to improve confidence in estimating the size of the effect, as well as to determine the
optimal strain and dosage. Future research should also explore the effectiveness of probiotics in children with different symptom profiles,
such as those with irritable bowel syndrome.
We found only a small number of trials of fibre-based interventions, with overall low-quality evidence for the outcomes. There was
therefore no convincing evidence that fibre-based interventions improve pain in children with RAP. Further high-quality RCTs of fibre
supplements involving larger numbers of participants are required. Future trials of low FODMAP diets and other dietary interventions
are also required to facilitate evidence-based recommendations.
P L A I N L A N G U A G E S U M M A R Y
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Review question
We reviewed the evidence on the effects of dietary interventions on pain in children aged between five and 18 years with recurrent
abdominal pain (RAP).
Background
Recurrent abdominal pain, or RAP, is a term used for unexplained episodes of stomachache or abdominal pain in children. Recurrent
abdominal pain is a common condition, and most children are likely to be helped by simple measures. However, a range of treatments
have been recommended to relieve abdominal pain, including making changes to the child’s eating habits by adding supplements or
excluding certain foods.
Study characteristics
This evidence is current to June 2016.
Nineteen studies met our inclusion criteria, including 13 studies of probiotics and four studies of fibre interventions. We also found
one study of a diet low in substances known as FODMAPs (fermentable oligosaccharides, disaccharides, monosaccharides and polyols)
and one study of a fructose-restricted diet.
All of the studies compared dietary interventions to a placebo or control. The trials were carried out in eight countries and included a
total of 1453 participants, aged between five and 18 years. Most children were recruited from outpatient clinics. Most interventions
lasted four to six weeks.
Key results
Probiotics
We found evidence from 13 studies suggesting that probiotics might be effective in improving pain in the shorter term. Most studies
did not report on other areas such as quality of daily life. No harmful effects were reported, other than dry mouth in one study. We
judged this evidence to be of moderate or low quality because some studies were small, showed varying results, or were at risk of bias.
Fibre supplements
We found no clear evidence of improvement of pain from four studies of fibre supplements. Most studies did not report on other areas
such as quality of daily life. No harmful effects were reported. There were few studies of fibre supplements, and some of these studies
were at risk of bias. We judged this evidence to be of low quality.
Low FODMAP diets
We found only one study evaluating the effectiveness of low FODMAP diets in children with RAP.
Fructose-restricted diets
We found only one study evaluating the effectiveness of fructose-restricted diets in children with RAP.
Conclusion
We found some evidence suggesting that probiotics may be helpful in relieving pain in children with RAP in the short term. Clinicians
may therefore consider probiotic interventions as part of the management strategy for RAP. Further trials are needed to find out how
effective probiotics are over longer periods of time and which probiotics might work best.
We did not find convincing evidence that fibre supplements are effective in improving pain in children with RAP. Future larger, high-
quality studies are needed to test the effectiveness of fibre and low FODMAP diet treatments.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Probiotics compared to placebo for recurrent abdominal pain in childhood
Patient or population: Children with recurrent abdominal pain
Settings: Mixed sett ings, including paediatric gastroenterology clinics
Intervention: Probiot ics
Comparison: Placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo Probiotics
Change in pain fre-
quency: 0 to 3 months’
postintervention
Dif ferent measures
were used to assess
pain f requency, such
as a visual analogue
scale and the Wong-
Baker FACES Pain Rat-
ing Scale (McGrath
1996; Wong 1988).
- The mean change in
pain f requency: 0 to
3 months’ post interven-
t ion scores in the inter-
vent ion groups was 0.
55 SDs lower (0.98 to
0.12 lower).
- 523
(6 studies)
⊕⊕©©
Low1,2
As a rule of thumb,
0.2 SD represents a
small dif f erence, 0.5 SD
a moderate dif ference,
and 0.8 SD a large dif -
ference
Change in pain inten-
sity: 0 to 3 months’
postintervention
Dif ferent mea-
sures were used to as-
sess pain intensity, as
above
- The mean change in
pain intensity: 0 to 3
months’ post interven-
t ion scores in the inter-
vent ion groups was 0.
50 SDs lower (0.85 to
0.15 lower).
- 575
(7 studies)
⊕⊕©©
Low1,2
As a rule of thumb,
0.2 SD represents a
small dif f erence, 0.5 SD
a moderate dif ference,
and 0.8 SD a large dif -
ference
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Improvement in pain: 0
to 3 months’ postinter-
vention
Dif ferent measures and
def init ions were used
for improvement in
pain, such as Likert
scale, visual analogue
scale, and Subject ’s
Global Assessment of
Relief Scale (McGrath
1996; Muller-Lissner
2003).
421 per 10003 542 per 1000
(438 to 642)
OR 1.63
(1.07 to 2.47)
NNTB = 8
722
(7 studies)
⊕⊕⊕©
M oderate4
-
Improvement in pain: 0
to 3 months’ postinter-
vention Subgroup (irri-
table bowel syndrome)
Dif ferent
measures were used to
assess improvement in
pain, as above
359 per 1000 627 per 1000
(498 to 742)
OR 3.01
(1.77 to 5.13)
NNTB = 4
344
(4 studies)
⊕⊕⊕©
M oderate5
-
Improvement in pain: 3
to 6 months’ postinter-
vention
Dif ferent
measures were used to
assess improvement in
pain, as above
589 per 1000 736 per 1000
(612 to 831)
OR 1.94
(1.10 to 3.43)
NNTB = 7
224
(2 studies)
⊕⊕⊕©
M oderate5
-
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; NNTB: number needed to treat for an addit ional benef icial outcome, based on the absolute risk reduct ion between the intervent ion and comparison
group probable outcomes; OR: odds rat io; SD: standard deviat ion.
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1Downgraded one level due to incomplete outcome data in a number of included studies leading to an unclear or high risk of
bias.
2Downgraded one level for evidence of signif icant heterogeneity (I² > 70%; Chi² P < 0.001).
3Assumed risk is based on the mean outcome of the control groups in all included studies.
4Downgraded one level due to evidence of heterogeneity (I² = 45%; Chi² P = 0.09).
5Downgraded one level for imprecision.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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B A C K G R O U N D
Description of the condition
This review is an update of a previously published review in
the Cochrane Library on ’Psychosocial interventions for recur-
rent abdominal pain and irritable bowel syndrome in childhood’
(Huertas-Ceballos 2009). Recurrent abdominal pain (RAP) is a
common problem in paediatric practice. It has been suggested
that 4% to 25% of school-aged children will at some point suf-
fer from recurrent or chronic abdominal pain that interferes with
their activities of daily living (Konijnenberg 2005;Williams 1996;
Youssef 2006), with a recent meta-analysis estimating that 13.5%
of children worldwide may be affected (Korterink 2015). Recur-
rent abdominal pain is often regarded as a relatively benign con-
dition, but it is important to note the associated morbidity and
the anxiety it causes for children and caregivers (Paul 2013). The
condition is associated with school absences, hospital admissions,
emotional disorders and, on occasion, unnecessary surgical in-
tervention (Scharff 1997; Stickler 1979; Størdal 2005; Walker
1998; Youssef 2008). The abdominal pain is also commonly as-
sociated with other symptoms, including headaches, recurrent
limbpains, pallor, and vomiting (Abu-Arafeh 1995;Devanarayana
2011; Hyams 1995). Symptoms sometimes continue into adult-
hood; childhood RAP is associated with a higher risk of anxiety
disorders in adults (Horst 2014; Shelby 2013).
Apley first sought to define the condition in the 1950s and sug-
gested that the diagnostic label should be based on the presence
of at least three episodes of severe abdominal pain (often, but
not necessarily, with associated systemic symptoms) over three
months (Apley 1958), with no established organic cause. Histor-
ically diverse terms have since been used to describe these condi-
tions, some implying causation. These include: “abdominal mi-
graine” (Bain 1974; Farquar 1956;Hockaday 1992; Symon1986),
“abdominal epilepsy” (Stowens 1970), “the irritable bowel syn-
drome in childhood” (Stone 1970), “allergic-tension-fatigue syn-
drome” (Sandberg 1973; Speer 1954), “neurovegetative dysto-
nia” (Peltonen 1970; Rubin 1967), “functional gastrointestinal
disorder” (Drossman 1995), and “the irritated colon syndrome”
(Harvey 1973; Painter 1964).
It is now generally accepted that RAP in children represents a
group of functional gastrointestinal disorders that have an unclear
aetiology. The latest Rome Foundation criteria state that such dis-
orders are defined by symptoms related to motility disturbance;
visceral hypersensitivity; altered mucosal and immune function;
altered gut microbiota; and altered central nervous system process-
ing, and are “the product of ... interactions of psychosocial fac-
tors and altered gut physiology via the brain-gut axis” (Drossman
2016). The Rome Foundation has produced criteria for this group
of conditions since 1994 by international consensus. Most studies
included in this review use the Rome III criteria from 2006, which
included a symptom-based classification system with specific cat-
egories for paediatric presentations (Rasquin 2006). Throughout
this review we have therefore used RAP as an umbrella term to
refer to the five subcategories included within the Rome III cat-
egory of childhood abdominal pain-related functional gastroin-
testinal disorders, which are: functional dyspepsia, irritable bowel
syndrome, abdominal migraine, functional abdominal pain, and
functional abdominal pain syndrome. It should be noted that the
pain classification for each of the Rome III diagnoses is defined by
at least one episode per week for at least two months; this varies
from Apley’s original definition of RAP (Apley 1958). The Rome
IV criteria were produced in spring 2016; in this new iteration
the category of childhood functional abdominal pain disorders in-
cludes functional dyspepsia, irritable bowel syndrome, abdominal
migraine, and functional abdominal pain not otherwise specified
(Drossman 2016). However, the Rome classification is not based
on known pathophysiological differences between the conditions,
but rather on the constellation of clinical features. It is unclear the
extent to which separating children into these categories defines
groups that are distinct clinical entities that are likely to respond
differently to treatment.
There is no consensus about which of the numerous proposed
causal pathways result in the heterogeneous presentations of
chronic abdominal pain, although it is suggested that physical,
emotional, and environmental factors may contribute to the man-
ifestation of unexplained abdominal pain. When considering the
diverse proposed mechanisms, it is unsurprising that a variety of
treatments have been suggested. The treatment approaches can be
grouped as pharmacological, dietary, or psychosocial (psycholog-
ical or behavioural, or both). This review focused on any inter-
vention with dietary changes intended to improve the symptoms
of RAP, and hence dietary approaches only are discussed below.
Updated companion reviews of pharmacological interventions,
Martin 2014a, and psychosocial interventions, Abbott 2017, for
RAP have been published.
Description of the intervention
Dietary interventions may involve excluding or reducing a food
group or specific ingredient from the diet or supplementing it and
therefore increasing its intake. Such dietary interventions include
eliminating or restricting food groups or food components, such
as dairy products or fructose (Bain 1974; Bayless 1971; Wirth
2014), and taking fibre supplements (Horvath 2013). Probiotics,
which are living micro-organisms such as Lactobacillus, have also
been used in managing children with RAP (Wilhelm 2008). More
recently there has been interest in the use of low FODMAP (fer-
mentable oligosaccharides, disaccharides, monosaccharides and
polyols) diets in the management of irritable bowel syndrome, al-
though the majority of studies have included adult populations
(Rao 2015), with one recent randomised controlled trial in chil-
dren (Chumpitazi 2015).
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How the intervention might work
Probiotic-based interventions containing living micro-organisms
are thought to improve symptoms through restoring the gut’s mi-
crobial balance. It has also been suggested that theymight alter the
intestinal inflammatory response in the lining of the gut (Quigley
2008). Fibre-based interventions might be effective in children
with irritable bowel syndrome in particular, by modifying bowel
habits and the transit time through the gut, as well as by decreas-
ing intracolonic pressure (Romano 2013). It has been suggested
that alterations in diet, such as low FODMAP interventions, may
work in irritable bowel syndrome by reducing osmotic effects, fer-
mentation, and gas production, hence decreasing distension and
pain (Nanayakkara 2016).
Why it is important to do this review
Recurrent abdominal pain in children is very common, and indaily
clinical practice there is no consensus on which treatments to offer
patients. The approach to treating RAP is therefore inconsistent.
This review, an update of one last carried out in 2009 (Huertas-
Ceballos 2009), is important to establish if there is new evidence
for the effectiveness of dietary interventions in children with RAP.
Together with updated reviews of pharmacological interventions,
Martin 2014a, and psychosocial interventions, Abbott 2017, for
RAP, this review can guide clinicians, patients, and their families
in treatment decisions.
O B J E C T I V E S
To examine the effectiveness of dietary interventions in improving
pain in children of school age with RAP.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs).
Types of participants
Children aged five to 18 years old with RAP or an abdominal
pain-related functional gastrointestinal disorder, as defined by the
Rome III criteria (Rasquin 2006).
Recurrent abdominal pain is defined as at least three episodes of
pain interfering with normal activities within a three-month pe-
riod. The Rome III criteria recognise five abdominal pain-related
categories: “abdominal migraine”, “irritable bowel syndrome”,
“functional dyspepsia”, “functional abdominal pain”, and “func-
tional abdominal pain syndrome” (Rasquin 2006).
Types of interventions
Any dietary intervention compared to placebo, waiting list, no
treatment, or standard care.
Types of outcome measures
Primary outcomes
1. Pain intensity, duration, or frequency.
There is no standard method for measuring pain in this condi-
tion. Studies may use any validatedmeasurement of pain, andmay
report the proportion of participants with significant improve-
ment in pain as defined by the trial author. We expected studies to
vary in their duration of postintervention follow-up. We therefore
grouped studies according to duration of follow-up: postinterven-
tion (immediately or the earliest data available following the end of
treatment), medium-term follow-up (three to six months’ postin-
tervention), and long-term follow-up (six months or longer). See
Differences between protocol and review.
Secondary outcomes
As measured by a validated tool:
1. school performance (to include measures such as school
functioning, behaviour, or school attendance);
2. social or psychological functioning (to include measures
such as anxiety or depression); and
3. quality of daily life (to include measures such as quality of
life or impairment to daily activities, functional disability, or
activity limitations).
We also reported on adverse events, where these were monitored.
See Differences between protocol and review.
We presented all outcomes in Summary of findings for the main
comparison and Summary of findings 2.
Search methods for identification of studies
Electronic searches
We ran the first literature searches in April 2013 and updated them
in April 2014, March 2015, and again in June 2016. We searched
the electronic databases and trial registers listed below.
1. Cochrane Central Register of Controlled Trials
(CENTRAL; 2016, Issue 5) in the Cochrane Library, and which
includes the Cochrane Developmental, Psychosocial and
Learning Problems Specialised Register (searched 10 June 2016).
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2. Ovid MEDLINE In-Process & Other Non-Indexed
Citations and Ovid MEDLINE (1946 to current; searched 9
June 2016).
3. Embase Ovid (1974 to current; searched 9 June 2016).
4. CINAHL Healthcare Databases Advanced Search
(Cumulative Index to Nursing and Allied Health Literature;
1981 to current; searched 9 June 2016).
5. PsycINFO Ovid (1806 to current; searched 9 June 2016).
6. ERIC ProQuest (Educational Resources Information
Center; 1966 to current; searched 9 June 2016).
7. BEI ProQuest (British Education Index; 1975 to current;
searched 9 June 2016).
8. ASSIA ProQuest (Applied Social Sciences Index and
Abstracts; 1987 to current; searched 9 June 2016).
9. AMED Healthcare Databases Advanced Search (Allied and
Complementary Medicine; 1985 to current; searched 9 June
2016).
10. LILACS (Latin American and Caribbean Literature in
Health Sciences; lilacs.bvsalud.org/en; searched 9 June 2016).
11. OpenGrey (opengrey.eu; searched 9 June 2016).
12. ClinicalTrials.gov (clinicaltrials.gov; searched 9 June 2016).
13. World Health Organization International Clinical Trials
Registry Platform (WHO ICTRP; apps.who.int/trialsearch;
searched 9 June 2016).
The search terms were revised from the original Cochrane
RAP reviews (Huertas-Ceballos 2008a; Huertas-Ceballos 2008b;
Huertas-Ceballos 2009); consequently, searches were run for all
available years. We used RCT filters where appropriate and im-
posed no language limits. We translated any non-English language
studies identified so that they could be screened and considered
for inclusion. The search strategies for each database are reported
in Appendix 1.
Searching other resources
Weused the ScienceCitation Index to locate relevant studies using
the bibliographic details, and authors’ names of relevant papers
for forward and backward citations. We contacted researchers who
have published studies in this field to ask for details of any relevant
trials. We also checked the bibliographies of papers retrieved to
establish if all pertinent references were found by our search.
Data collection and analysis
Selection of studies
Two review authors (TVN, AEM, RAA, AB, or RW) indepen-
dently screened the titles and abstracts of studies for relevance.
We obtained the full-text reports of all potentially relevant papers
and screened them for inclusion against the eligibility criteria (see
Criteria for considering studies for this review). Any disagreements
were resolved through discussionwith a third review author (JTC).
We recorded our decisions in a PRISMA diagram (Moher 2009).
Data extraction and management
Two review authors (TVN, AEM, RAA, AB, JTC, or RW) ex-
tracted the data and entered the data into Cochrane’s statistical
software, Review Manager 5 (Review Manager 2014). All review
authors used the same data extraction form. We collected the fol-
lowing data.
1. Study characteristics: number of participating children,
inclusion and exclusion criteria, type of intervention and
comparison, intervention characteristics (duration, frequency,
setting), number of withdrawals.
2. Participant characteristics: sex, age, diagnosis (e.g. RAP or
other syndrome, as defined by the Rome III criteria) (Rasquin
2006).
3. Outcome measures: measurement of pain and any
secondary outcomes measured. See Types of outcome measures.
Assessment of risk of bias in included studies
We assessed the risk of bias of each included study using the
Cochrane ’Risk of bias’ tool (Higgins 2011a). We assessed the fol-
lowing categories of bias: selection bias (random sequence gener-
ation and allocation concealment), performance bias (blinding of
participants and personnel), detection bias (blinding of outcome
assessment), attrition bias (incomplete outcome data), reporting
bias (selective reporting), and other potential sources of bias that
could have altered the estimate of treatment effect; for example,
any evidence of differential loss to follow-up, whether the data
collection tools were valid, whether there was sufficient power in
terms of appropriate sample size, whether baseline parameters were
similar, and whether data analyses were appropriate. Two review
authors (TVN, AEM, RAA, AB, JTC, or RW) independently as-
sessed and classified each study as being at ’low’, ’high’, or ’unclear’
risk of bias across each of these domains, based on the methods
detailed in the Cochrane Handbook for Systematic Reviews of Inter-
ventions (Higgins 2011a); see Table 1 for more information. We
considered a trial as having an overall low risk of bias if most of
the above categories of bias were assessed as low risk of bias.
Measures of treatment effect
We reported our study results as follows.
Continuous data
For continuous data (e.g. pain intensity or frequency), we analysed
means and standard deviations (SDs), where available or could
be calculated, and providing there was no clear evidence of skew
in the distribution. When different scales were used to measure
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the same clinical outcome, we combined standardised mean dif-
ferences (SMDs) across the studies. We presented the pooled esti-
mates with 95% confidence intervals (CIs).
Dichotomous data
For dichotomous data (e.g. pain improved, yes or no), we analysed
the data using odds ratios (ORs) and 95% CIs.
The definition of pain improvement varied across the studies. We
used the author definition of improvement.
Unit of analysis issues
Cross-over trials
We considered the results of this type of trial using the guidance
in the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011b), in particular assessing whether an appropriate
washout period was used. Given that RAP can be a stable and
chronic condition, we considered a washout period of two to three
weeks to be sufficient.
Please see Appendix 2 and our protocol, Martin 2014b, for ad-
ditional methods for handling unit-of-analysis issues archived for
use in future updates of this review.
Dealing with missing data
In the few cases where there were missing data, such as standard
deviations, we contacted the original investigators to request if the
missing data were available. When it was not possible to obtain
the data from the original investigators, we did not impute values;
this was a decision made a priori in our protocol (Martin 2014b).
Studies for which authors provided additional data not originally
published are detailed in the Characteristics of included studies.
Assessment of heterogeneity
We anticipated finding considerable heterogeneity among in-
cluded studies. We assessed clinical heterogeneity by examining
the distribution of relevant participant characteristics (e.g. age,
definition of RAP) and study differences (e.g. concealment of ran-
domisation, blinding of outcome assessors, interventions, or out-
come measures). We described the statistical heterogeneity (ob-
served variability in study results that is greater than that expected
to occur by chance) by reporting the I² statistic (Higgins 2003).
The I² statistic describes approximately the proportion of variation
in point estimates due to heterogeneity rather than sampling error.
A value of more than 50% may indicate significant heterogeneity.
We used the Chi² test to further assess the strength of evidence
of the heterogeneity. We regarded any result with a P value lower
than 0.10 as indicating significant statistical heterogeneity.We in-
terpreted this cautiously and used it to help quantify the impact
of heterogeneity on the results of the meta-analysis and ultimately
on the GRADE quality rating (see Data synthesis). We also re-
portedTau²when using the random-effectsmodel (seeDifferences
between protocol and review), which provides an estimate of the
between-study variance (Deeks 2011).
Assessment of reporting biases
We did not have more than 10 trials for each outcome, and so did
not perform these analyses (see Appendix 2; Martin 2014b).
Data synthesis
We used Review Manager 5 for statistical analysis (Review
Manager 2014). Two review authors (TVN, AEM, RAA, AB,
JTC) independently entered data into Review Manager 5 (Review
Manager 2014).
We anticipated significant statistical and clinical heterogeneity.We
reported summary statistics for continuous data as mean differ-
ences (MDs) or SMDs using a random-effects model, weighted
using the inverse-variance method. For dichotomous data, we also
used a random-effects model and calculated the ORs using Man-
tel-Haenszel methods, as this has been shown to have better statis-
tical properties where event rates are low or study size small (Deeks
2011).
We only conducted meta-analyses if it was appropriate to do so,
that is if the studies were sufficiently homogeneous. We thus only
carried out a meta-analysis using data from studies with equivalent
dietary interventions. Where meta-analysis was not appropriate,
we provided a narrative description of the results.
For all outcomes where we conducted a meta-analysis, we pro-
duced a ’Summary of findings’ table detailing the number of trials
and participants, the results of the analysis, and the GRADE rat-
ing of quality of evidence for the outcome; the procedure for this
is described below.
Assessing the quality of evidence for each outcome
We used the GRADE approach to assess the overall quality of
the body of evidence for a specific outcome (The Grade Working
Group 2013). We used GRADEpro software to assess and present
the findings in the ’Summary of findings’ tables (GRADEpro
GDT 2015).We completed a ’Summary of findings’ table for each
main treatment comparison (Summary of findings for the main
comparison; Summary of findings 2).
For the dichotomous outcome of pain improvement, we calcu-
lated the probable outcome of events per 1000 for both the control
group and those receiving the intervention, following the guid-
ance in the Cochrane Handbook for Systematic Reviews of Interven-
tions (Schünemann 2011a), similar to other reviews that include
people with pain conditions (e.g. Eccleston 2014). We judged the
studies included for each outcome using five criteria: risk of bias,
indirectness, inconsistency, imprecision, and publication bias. We
used limitations in the design and implementation to assess the
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overall risk of bias of included studies for each outcome, down-
grading an outcome if the majority of studies had unclear or high
risk of bias. We assessed indirectness if a population, intervention,
or outcome was not of direct interest to the review. Inconsistency
was determined by the heterogeneity of results. If there was ev-
idence of significant statistical heterogeneity (see Assessment of
heterogeneity), we downgraded the quality of the outcome. We
assessed imprecision by the number of participants included in an
outcome and by CIs; we downgraded outcomes when only a small
number of participants could be included in the analysis or the
analysis had wide CIs. Finally, we downgraded for publication bias
if studies failed to report outcomes in the published manuscript or
if there was a suspicion that null findings had not been published
or reported (Schünemann 2011b).
We gave each outcome a quality rating ranging from ’very low’
to ’high’. High-quality ratings are given when “further research is
unlikely to change our estimate of effect”.Moderate-quality ratings
are given when “further research is likely to have an important
impact on our confidence in the estimate of effect andmay change
the estimate”. Low-quality ratings are givenwhen “further research
is very likely to have an important impact on our confidence in the
estimate of effect and is likely to change the estimate”. Finally, very
low-quality ratings are given when “we are very uncertain about
the estimate” (Balshem 2011).
Subgroup analysis and investigation of heterogeneity
Where data were available, we carried out subgroup analyses by
subtype of RAP and by duration of follow-up, as specified in our
protocol (Martin 2014b).
Sensitivity analysis
In our protocol we planned to carry out sensitivity analyses to
assess the robustness of our conclusions in relation to two aspects
of study design (Martin 2014b). We intended to assess: 1) the
effect of inadequate allocation concealment, and 2) the effect of
inadequate blinding to treatment, by removal of studies judged to
be at high or unclear risk of bias in these domains. We performed
sensitivity analyses where pooled analyses included such studies.
R E S U L T S
Description of studies
For a full description of the main characteristics of the stud-
ies, including details on participants and setting, intervention
aspects, and outcome measures, see: Characteristics of included
studies; Characteristics of excluded studies; Characteristics of
studies awaiting classification.
Results of the search
For this updated review, we chose to redesign the search strategy in
order to include the recognised terms for different types of RAP, as
defined by the Rome criteria (Rasquin 2006). Consequently, we
ran our searches across the databases with no date restriction. The
results of the searching and screening are shown in the PRISMA
flow chart (Figure 1). We screened a total of 9649 titles and ab-
stracts, of which 231 were carried forward for further screening
at full text. We excluded 203 reports at full text and included 27
reports (19 studies) in the review. One study is awaiting classifica-
tion (Jarocka-Cyrta 2002).
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Figure 1. PRISMA study flow diagram
Included studies
We included 19 studies in this review, which were reported in 27
papers, four of which were included in the previous version of
our review (Bausserman 2005; Feldman 1985; Gawronska 2007;
Young 1997). Two of the included studies were only reported
as abstracts, and we were unable to obtain further details of the
methods or results; either we could not contact the authors of the
studies or the authors were unable to provide the details requested
(Sabbi 2011; Young 1997). However, based on the data in the
abstracts, the studies met the inclusion criteria (Sabbi 2011; Young
1997).
Thirteen studies were trials of probiotic-based interventions
(Asgarshirazi 2015; Bausserman 2005; Eftekhari 2015; Francavilla
2010; Gawronska 2007; Giannetti 2017; Guandalini 2010;
Kianifar 2015; Romano 2010; Sabbi 2011; Saneian 2015;
Weizman 2016; Young 1997), and four studies were trials of fi-
bre-based interventions (Feldman 1985; Horvath 2013; Romano
2013; Shulman 2016). One study was a trial of a low FODMAP
diet (Chumpitazi 2015), and one was a trial of a fructose-restricted
diet (Wirth 2014). All included studies were written in English.
We contacted the authors of Romano 2010 and Shulman 2016,
and they provided raw data for pain frequency and intensity out-
comes, as these were not included in the published paper. The au-
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thors of Asgarshirazi 2015 also provided additional data. For more
information, please see below and the Characteristics of included
studies tables.
Participants
The 19 included studies involved a total of 1453 children. Thir-
teen studies, with a total of 1017 children, investigated the effects
of probiotics versus placebo (Asgarshirazi 2015; Bausserman 2005;
Eftekhari 2015; Francavilla 2010; Gawronska 2007; Giannetti
2017; Guandalini 2010; Kianifar 2015; Romano 2010; Sabbi
2011; Saneian 2015; Weizman 2016; Young 1997). Four stud-
ies, with a total of 299 children, investigated the effects of fibre-
based interventions versus placebo (Feldman 1985;Horvath 2013;
Romano 2013; Shulman2016). The single study of the FODMAP
diet versus typical diet included 34 children (Chumpitazi 2015),
and the trial of a fructose-restricted diet included 103 children
(Wirth 2014). Eleven included trials randomised between 50 and
90 children; the smallest study included only 11 children (Young
1997), and the six largest more than 100 each (Asgarshirazi 2015;
Francavilla 2010; Gawronska 2007; Shulman 2016; Weizman
2016; Wirth 2014). Participants were aged between four and 18
years, with the mean age at recruitment ranging from 6.3 years
to 13.1 years. Girls outnumbered boys in most included trials.
Fourteen trials recruited children with a diagnosis under the broad
umbrella of RAP or functional gastrointestinal disorders; five trials
specifically recruited only children with irritable bowel syndrome
(Bausserman 2005; Chumpitazi 2015; Guandalini 2010; Kianifar
2015; Shulman 2016). In Shulman 2016, children were only ran-
domised if they first failed to respond to an eight-day exclusion
diet eliminating carbohydrates (defined as 75% or less improve-
ment in abdominal pain frequency and severity).
Settings
The majority of studies took place in paediatric gastroenterology
clinics. In Francavilla 2010, children were recruited from primary
care paediatric practices, and in Feldman 1985 children came from
private general practice practices and community paediatric clin-
ics. Children in Shulman 2016 andWeizman 2016 came from care
networks, including both primary and tertiary care. Chumpitazi
2015 advertised for participants from community settings as well
as recruiting from paediatric gastroenterology clinics.
Location
Trials took place across eight countries. Six studies were con-
ducted in Italy (Francavilla 2010; Giannetti 2017; Guandalini
2010; Romano 2010; Romano 2013; Sabbi 2011), four in Iran
(Asgarshirazi 2015; Eftekhari 2015; Kianifar 2015; Saneian 2015),
four in the USA (Bausserman 2005; Chumpitazi 2015; Shulman
2016; Young 1997), two in Poland (Gawronska 2007; Horvath
2013), and one each in Canada (Feldman 1985), Israel (Weizman
2016), Germany (Wirth 2014), and India (Guandalini 2010).
Interventions
We classified interventions into four groups: probiotic-based in-
terventions, fibre-based interventions, low FODMAP-based diet
interventions, and fructose-restricted diets. We did not include
peppermint oil as a dietary intervention but categorised it as phar-
macological; trials of this intervention are therefore considered in
the companion pharmacological review (Martin 2014a).
Probiotic interventions
Thirteen trials used probiotic-based interventions. Not all tri-
als assessed the same probiotic-based intervention. Five trials
used Lactobacillus rhamnosusGG in slightly different preparations
(Bausserman 2005; Francavilla 2010; Gawronska 2007; Kianifar
2015; Sabbi 2011). Three other trials used Lactobacillus reuteri
(Eftekhari 2015; Romano 2010; Weizman 2016). The probiotic
in Young 1997 wasLactobacillus plantarum (LP299V).Guandalini
2010 was a cross-over trial where the intervention was VSL#3, a
probiotic preparation of different strains. Giannetti 2017 was a
cross-over trial using a mixture of three Bifidobacterium species.
Saneian 2015 and Asgarshirazi 2015 used Bacillus coagulans plus
fructo-oligosaccharides. The treatment period ranged from four
weeks, in Asgarshirazi 2015, Bausserman 2005, Eftekhari 2015,
Gawronska 2007, Kianifar 2015, Romano 2010, Saneian 2015,
and Weizman 2016, to eight weeks, in Francavilla 2010. In most
studies, outcomes were measured immediately postintervention;
the longest period of follow-up was 16 weeks, in Francavilla 2010.
Only two studies measured outcomes at three to 12 months’
postintervention (Francavilla 2010; Saneian 2015).
Fibre interventions
Four trials used fibre-based interventions. These included a fibre
biscuit containing 5 g of corn fibre (Feldman 1985), a prepara-
tion of partially hydrolysed guar gum (PHGG) (Romano 2013),
a preparation of glucomannan (GNN) (Horvath 2013), and psyl-
lium fibre (Shulman 2016). The treatment period ranged from
four weeks, in Romano 2013 and Horvath 2013, to six weeks, in
Feldman 1985 and Shulman 2016. Three of the studies measured
outcomes immediately postintervention (Feldman 1985;Horvath
2013; Shulman 2016), and the fourth measured outcomes im-
mediately postintervention and four weeks afterwards (Romano
2013).
Low FODMAP interventions
Only one included trial examined a low FODMAP diet interven-
tion. Chumpitazi 2015 was a cross-over trial comparing a two-
day low FODMAP diet intervention with a control of a typical
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American childhood diet (TACD). Outcomes were measured im-
mediately after intervention at two days.We found no other RCTs
of low FODMAP diets.
Fructose-restricted diets
We found one trial of a fructose-restricted diet (Wirth 2014),
where participants with RAP for more than three months were
randomised to a specified low-fructose diet or a standard diet for
two weeks, with outcomes measured immediately postinterven-
tion.We found no other eligible RCTs of this type of intervention.
Comparators
All included trials assessed the dietary intervention against a
placebo comparison, with the exception of Chumpitazi 2015
and Wirth 2014, where the comparator was a standard diet.
Asgarshirazi 2015 was a three-arm trial where probiotics were com-
pared against peppermint oil and placebo; however, only the pro-
biotics versus placebo comparison was reported in this review.
Outcomes
The primary outcomes of this review related to abdominal pain,
andpain outcomeswere reported in every trial. Studies reported on
pain in terms of pain improvement (usually defined as a percentage
or number of points improved from baseline, or being pain-free),
pain severity/intensity, or pain frequency; or a combination of all
three. Painwasmost commonly assessed using versions of the Faces
Pain Scale (Bieri 1990; McGrath 1996; Wong 1988), or by using
a standard visual analogue scale, typically with a range of 0 to 10.
Other studies used more general measures to assess improvement
in symptoms, including pain, such as the Subject’s Global Assess-
ment of Relief Child version (SGARC) (Muller-Lissner 2003). A
number of studies specified that the outcome was child reported
(Francavilla 2010; Gawronska 2007; Guandalini 2010; Shulman
2016). In other studies it was not specified whether the parent or
child was completing the measure, or it was stated that pain was
reported by “child or family/parent”. As the age range in most
studies was wide, this is likely to have influenced who was re-
porting on the measures. Authors usually reported that pain was
assessed on a daily basis (Asgarshirazi 2015; Bausserman 2005;
Chumpitazi 2015; Feldman 1985; Francavilla 2010; Giannetti
2017; Guandalini 2010; Romano 2010; Shulman 2016;Weizman
2016). Wirth 2014 reported that symptoms were recorded at the
end of the intervention. In the remaining studies the frequency of
measure completion was not clearly described.
Secondary outcomes included in this review were school perfor-
mance, social or psychological functioning, and quality of daily
life. Not all studies measured these outcomes. Gawronska 2007,
Horvath 2013, and Weizman 2016 reported on school absen-
teeism, and Guandalini 2010 and Horvath 2013 reported on dis-
ruption of daily activities. Participants in Kianifar 2015 reported
on both absence from school and disruption of social activities
as part of functional changes on a three-point Likert scale. In
Giannetti 2017, participants completed the Functional Disabil-
ity Inventory (Claar 2006), which assesses physical and psychoso-
cial functions and quality of life. In Shulman 2016, participants
completed Paediatric Quality of Life Generic Core Scales (Varni
2015).
Adverse events
All studies except Feldman 1985 and Wirth 2014 reported that
they monitored children for adverse events. This information was
not available in the two included abstracts, and the authors either
did not respond to requests for further information (Sabbi 2011),
or they were unable to provide details (Young 1997).
Funding
Ten studies did not report their source of funding (Asgarshirazi
2015; Feldman 1985; Francavilla 2010; Giannetti 2017; Horvath
2013; Romano 2010; Romano 2013; Weizman 2016; Wirth
2014; Young 1997). Four studies reported being funded by their
university (Eftekhari 2015; Gawronska 2007; Kianifar 2015;
Saneian 2015); one was funded by “locally available grants”, al-
though the intervention and placebo were provided by industry
(Guandalini 2010), and one study was funded by a university seed
grant (Bausserman 2005). Shulman 2016 was funded by various
organisations, including the US National Institutes of Health and
the US Department of Agriculture. Chumpitazi 2015 was funded
by an academic society in conjunction with Nestlé and the Na-
tional Institutes of Health.
Excluded studies
The PRISMA diagram (Figure 1) outlines the number of studies
excluded at the full-text screening stage (n = 231). The major-
ity of these clearly involved an ineligible population (e.g. adults)
or ineligible interventions (psychosocial or pharmacological), and
therefore we have not listed or described these further. However,
we excluded six studies for less obvious reasons, and have described
these here and listed them in theCharacteristics of excluded studies
section.
We excluded three studies that were included in the 2009 re-
view, Huertas-Ceballos 2009, on the grounds of study design
(Christensen 1982; Dearlove 1983; Lebenthal 1981). Christensen
1982 and Dearlove 1983 did not appear to be RCTs. It was also
unclear whether participants in Lebenthal 1981 were randomised,
and as we were unable to clarify this with the authors, we also
excluded this study.
From our updated search in 2016, we excluded one study that was
not a RCT (Agah 2015). We excluded two further studies because
they used ineligible comparators (Chumpitazi 2014; Edwards
1991).
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Risk of bias in included studies
We rated all included studies for risk of bias across the following
categories: random sequence generation (selection bias), allocation
concealment (selection bias), blinding of participants and person-
nel (performance bias), blinding of outcome assessment (detection
bias), incomplete outcome data (attrition bias), selective reporting
(reporting bias) and other potential sources of bias (other bias).
Figure 2 displays the review authors’ assessments of risk of bias
for each study individually, and Figure 3 represents the authors’
judgements about each risk of bias item presented as percentages
across all included studies.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Figure 3. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Allocation
We rated no studies as being at high risk of bias in this domain.
Random sequence generation
We judged that themajority of studies had adequately randomised
their participants as they used appropriate methods of randomi-
sation as detailed in Table 1, such as computer-generated ran-
dom numbers. The exceptions were Asgarshirazi 2015, Eftekhari
2015, and Wirth 2014, all of which we rated as being at unclear
risk in this domain due to insufficient detail provided about how
randomisation was performed. We also rated the two studies for
which only abstracts were available as at unclear risk of bias in this
domain due to insufficient detail provided about randomisation
(Sabbi 2011; Young 1997).
Allocation concealment
The most frequently encountered issue in assessing the risk of
selection bias was poorly described allocation sequence conceal-
ment. The authors of seven studies provided insufficient detail on
how this was done, leading to an assessment of unclear risk of
bias (Asgarshirazi 2015; Eftekhari 2015; Feldman 1985; Romano
2013; Sabbi 2011; Wirth 2014; Young 1997).
Blinding
Blinding of participants and personnel
Most studies described the use of identical placebos and double-
blinding of participants and personnel, and so we judged them to
be at low risk of performance bias. However, we rated Asgarshirazi
2015 as being at unclear risk of bias for this outcome, as although
the study was blinded, the placebo regimen of folic acid tablets
was different in timing and frequency to the intervention regimen,
and the authors did not discuss the possible impact of this. In
Chumpitazi 2015, the study was described as double-blinded, but
it was unclear whether the intervention and control diets were
delivered in identical containers or what clues there might have
been to the allocation, hence we also rated this study as being at
unclear risk of bias. We rated one study as being at high risk of bias
for this domain, as the children who rated their own symptoms
were not blinded (Wirth 2014).
Blinding of outcome assessment
Outcomes were assessed by parents, children, and clinicians; the
issues described above regarding blinding of participants and per-
sonnel also applied to the blinding of outcome assessment, conse-
quently we rated all studies as being at low risk of bias for this do-
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main with the exception of Asgarshirazi 2015, Chumpitazi 2015,
Sabbi 2011, and Wirth 2014.
Incomplete outcome data
We rated 10 studies as being at unclear risk of attrition bias; many
studies did not fully report outcome data, making it difficult to
assess the risk of attrition bias (Asgarshirazi 2015; Eftekhari 2015;
Horvath 2013;Kianifar 2015;Romano 2010; Sabbi 2011; Saneian
2015;Weizman 2016;Wirth 2014; Young 1997). For example, in
Asgarshirazi 2015, 32 children were excluded during the trial after
randomisation and not analysed because they did not complete
the one-month intervention; according to the authors this was
“due to journey or lack of 2 weeks visit”, but information was
insufficient to determine if this could have resulted in attrition
bias. Also, in Weizman 2016, the authors state that an intention-
to-treat analysis was carried out, but the paper also states that eight
participants were excluded due to “poor compliance and violation
of the protocol” and not analysed, hence the exact methodology
was unclear. Again, for the two studies for which only abstracts
were available, insufficient detail was provided, so they too were
rated as being unclear risk of bias for this domain (Sabbi 2011;
Young 1997).
Selective reporting
We did not rate any studies as being at high risk of bias for this do-
main. Feldman 1985 presented insufficient information to assess
reporting bias and so was judged to be at unclear risk of bias. We
also judged Guandalini 2010 to be at unclear risk of reporting bias
as comparisons were made pre/post and not between intervention
and control at six weeks. Again, for the two studies for which only
abstracts were available, insufficient detail was provided, so they
too were rated as being unclear risk of bias for this domain (Sabbi
2011; Young 1997).
Other potential sources of bias
We rated the risk of other potential biases (such as validity of
data collection tools, appropriate sample size, similarity of baseline
details) as low for included studies for which we had the full text,
as we did not find any othermajor sources of bias that would likely
affect the results. The exceptions were Asgarshirazi 2015, which
we rated at high risk of bias as there were imbalances in measures
of pain at baseline;Wirth 2014, which we rated as being at unclear
risk of bias as no details were given regarding the use of validated
tools or of adherence; and Sabbi 2011 and Young 1997, which we
also rated at unclear risk of bias due to insufficient information in
the abstracts.
Effects of interventions
See: Summary of findings for the main comparison Probiotics
compared to placebo for recurrent abdominal pain in childhood;
Summary of findings 2 Fibre versus placebo for recurrent
abdominal pain in childhood
We were able to perform a total of 10 analyses across the studies.
We performed analyses within intervention type, as the mecha-
nisms of action of each dietary intervention are different. We only
performed analyses on those studies that provided equivalent out-
come data in comparable formats, therefore not all studies within
each intervention type were entered into the analyses.
For probiotic-based interventions, we were able to perform three
analyses for our primary outcomes (effects on pain frequency, pain
intensity, and pain improvement), at zero to three months’ postin-
tervention. As four studies included only children with irritable
bowel syndrome, or reported outcomes for this group separately,
as per our protocol (Martin 2014b), we were also able to perform
a subgroup analysis for this group for the outcome of improve-
ment in pain at zero to three months’ postintervention. We were
able to perform one analysis for the outcome of improvement in
pain at three to six months’ postintervention. We also were able
to perform sensitivity analyses for three outcomes, by removing
studies judged to be at unclear or high risk of bias in the domains
of allocation concealment, blinding of participants and personnel,
and/or blinding of outcome assessment.
For fibre-based interventions, we were able to perform two anal-
yses: effect on pain improvement and change in pain intensity
postintervention (zero to three months).
We were unable to perform any analyses for low FODMAP diet
interventions or for fructose-restricted diets, as we found only one
study in each category eligible for inclusion.
We were unable to perform any pooled analyses of secondary out-
comes for any dietary intervention, as these were either not re-
ported or reported in formats that were not comparable. The re-
sults of individual studies are briefly presented below, followed by
the results of the pooled analyses.
We assessed the quality of evidence using theGRADEcriteria (The
Grade Working Group 2013), and presented our ratings in ’Sum-
mary of findings’ tables, which we constructed using GRADEpro
software (GRADEpro GDT 2015). Within probiotic-based in-
terventions, we scored the evidence for the three improvement in
pain outcomes as moderate quality, meaning that further research
is likely to have an important impact on our confidence in the
estimate of effect and may change the estimate. For the change
in pain intensity and frequency outcomes, we rated the evidence
as low quality, meaning that future research is likely to have an
important impact on our confidence in the estimate of effect and
is likely to change the estimate. See Summary of findings for the
main comparison. For fibre-based interventions, we rated the ev-
idence for the change in pain intensity and improvement in pain
outcomes as low quality. See Summary of findings 2.
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Comparison 1: Probiotic interventions versus placebo
Thirteen included studies assessed the effects of probiotics (
Asgarshirazi 2015; Bausserman 2005; Eftekhari 2015; Francavilla
2010; Gawronska 2007; Giannetti 2017; Guandalini 2010;
Kianifar 2015; Romano 2010; Sabbi 2011; Saneian 2015;
Weizman 2016; Young 1997).
Primary outcomes
Results of individual studies
Here, we briefly present the results of the individual studies (please
note, we could only provide exact P values when these were avail-
able in the original report).
Change in pain frequency, change in pain intensity, and
improvement in pain
Asgarshirazi 2015 reported on pain severity, duration, and fre-
quency immediately following a four-week intervention with
Bacillus coagulans plus fructo-oligosaccharides. Mean decrease in
pain duration and pain frequency was greater in the probiotic
group compared to the placebo group (P = 0.012 and P < 0.001,
respectively).
Bausserman 2005 reported no difference between the probiotic
arm and placebo arm in response to treatment, defined as improve-
ment in abdominal pain of one or more levels, at six weeks (OR
1.18, 95% CI 0.38 to 3.63). There was also no difference between
the two groups in terms ofmean change in pain (P = 0.175) asmea-
sured by the Gastrointestinal Symptoms Rating Scale (Svedlund
1988).
Eftekhari 2015 reported no significant difference in pain inten-
sity, pain frequency, or improvement in pain between probiotic
and placebo arms at four and eight weeks’ postintervention. At
both time points, pain intensity and severity in both groups were
significantly reduced from baseline (P < 0.001).
Francavilla 2010 reported results at eight and 16 weeks’ postin-
tervention. At eight weeks, treatment success was experienced by
72% of children in the probiotic group and 53% of children in the
placebo group (OR2.18, 95%CI 1.07 to 4.45), and the difference
was maintained at 16 weeks (79% intervention, 62% control; P <
0.03). Pain intensity was lower in the intervention group at eight
weeks (P < 0.01), and pain frequency was reduced at eight weeks
(P < 0.01) and 12 weeks (P < 0.02).
Gawronska 2007 reported that at four weeks, 25% of the inter-
vention group experienced treatment success in terms of no pain
compared to 9.6% of the placebo group (OR 3.1, 95% CI 1.03 to
9.56). Overall, 25 children receiving probiotics experienced im-
provement in pain compared to 23 receiving placebo (OR 1.17,
95%CI 0.62 to 2.21). No other significant differences in outcome
measure were reported, including change in pain frequency and
intensity.
Guandalini 2010 reported only pre/post comparisons on change
in pain frequency and intensity at week six, and we could obtain
no additional information for these outcomes to enter in themeta-
analysis. At six weeks, 44 of 59 children experienced an improve-
ment in pain in the intervention arm of the cross-over, compared
to 29 children in the placebo group (OR 3.03, 95% CI 1.4 to
6.6).
Giannetti 2017 was a cross-over RCT with a six-week treatment
period and a two-week washout period. The primary outcome
was being pain-free at six weeks. In children with irritable bowel
syndrome, 42% experienced full resolution on probiotic versus
14% on placebo (P = 0.003); in those with functional dyspepsia
there was no improvement (21% versus 32%; P = 0.5).
Kianifar 2015 measured pain severity at four weeks; the mean
score in the probiotic group was significantly lower than the mean
score in the placebo group at this time point (P < 0.001).
In Romano 2010, the intervention group experienced a significant
decrease in pain intensity at eight weeks (P < 0.001), and both
groups had a decrease in pain frequency at the same time point (P
< 0.05).
Sabbi 2011 reported outcomes at six and10weeks. In the probiotic
group, there was a significant reduction of both frequency (P <
0.01) and severity (P < 0.01) of abdominal pain at six weeks. These
differences were still present at 10-week follow-up (P < 0.02 and
P < 0.001, respectively).
In Saneian 2015, a higher proportion of children in the interven-
tion group (60%) compared to the control group (39.5%) were
defined as treatment responders at four weeks (P = 0.044), but
this difference was not sustained at 12 weeks (64.4% intervention,
53.4% control; P = 0.204). The authors reported no statistically
significant difference between intervention and control in terms
of physician-rated global pain severity or global improvement.
In Weizman 2016, pain intensity was significantly reduced in the
intervention group compared to the placebo group at four weeks
(P < 0.01) and eight weeks (P < 0.02); the difference in pain
frequency was significant at four weeks (P < 0.02) but was not
sustained at eight weeks (P = 0.09).
Young 1997 was a cross-over RCT. In the abstract the authors
report that children treated with probiotic had a significant re-
duction in symptoms at four weeks when compared to baseline,
whereas placebo treatment did not produce significant improve-
ment.
Results of pooled analyses
See Summary of findings for the main comparison.
Change in pain frequency
19Dietary interventions for recurrent abdominal pain in childhood (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
We pooled data from six studies at zero to three months’ postin-
tervention in a meta-analysis to examine change in pain frequency
(Asgarshirazi 2015; Eftekhari 2015; Francavilla 2010; Gawronska
2007; Romano 2010; Weizman 2016). The SMD of effect across
the studies was -0.55 (95% CI -0.98 to -0.12; Z = 2.52; P = 0.01;
523 children; Analysis 1.1). However, there was significant statis-
tical heterogeneity (Tau² = 0.23; Chi² = 28.10; I² = 82%; P for
heterogeneity < 0.001). Using GRADE, we rated the quality of
evidence for this outcome as low, downgrading it two levels due to
risk of bias in the included studies and the statistical heterogeneity.
For our planned sensitivity analysis, we identified two included
studies where there was an unclear risk of bias in relation to alloca-
tion concealment or blinding of participants and personnel and/
or blinding of outcome assessment (Asgarshirazi 2015; Eftekhari
2015), and repeated the pooled analysis after excluding these two
studies. The estimate of effect was a SMD of -0.54 (95% CI -0.94
to -0.14; Z = 2.62; P = 0.009; 4 studies; 389 children; Tau² = 0.12;
Chi² = 11.24; I² = 73%; P for heterogeneity = 0.01; Analysis 1.2).
Removing these studies therefore did not appreciably change the
estimate of effect from the main analysis in Analysis 1.1.
Change in pain intensity
We entered data from seven studies into the meta-analysis of
change in pain intensity (Asgarshirazi 2015; Eftekhari 2015;
Francavilla 2010;Gawronska 2007;Kianifar 2015;Romano 2010;
Weizman 2016). The SMD of effect across the studies was -0.50,
(95% CI -0.85 to -0.15; Z = 2.80; P = 0.005; 575 children;
Analysis 1.3), and again there was considerable statistical hetero-
geneity (Tau² = 0.17; Chi² = 24.95; I² = 76%; P for heterogene-
ity < 0.001). Using GRADE, we rated the quality of evidence for
this outcome as low, downgrading it two levels due to risk of bias
in the included studies and the statistical heterogeneity. We were
able to perform a sensitivity analysis (again excluding Asgarshirazi
2015 and Eftekhari 2015). The estimate of effect in the sensitivity
analysis was a SMD of -0.68 (95% CI -1.05 to -0.30; P = 0.001; 5
studies; 441 children; Tau² = 0.13; Chi² = 14.00; I² = 71%; P for
heterogeneity = 0.007; Analysis 1.4). Again, this did not result in
appreciable change to the estimate of effect from themain analysis
in Analysis 1.3.
Improvement in pain
Seven studies (722 children) were eligible for meta-analysis
for the outcome of improvement in pain (Bausserman 2005;
Eftekhari 2015; Francavilla 2010; Gawronska 2007; Giannetti
2017;Guandalini 2010; Saneian2015). TheOR for pain improve-
ment at zero to three months’ postintervention was 1.63 (95% CI
1.07 to 2.47; Z = 2.27; P = 0.02; Tau² = 0.14; Chi² = 10.98; I²
= 45%; P for heterogeneity = 0.09; Analysis 1.5), with eight as
the number needed to treat for an additional beneficial outcome
(NNTB) (see Figure 4). Using GRADE, we rated the quality of
the evidence for this outcome as moderate, downgrading it one
level due to evidence of statistical heterogeneity. In this analysis,
the heterogeneity appeared to have been introduced by one of the
new studies in the update search (Eftekhari 2015); prior to its in-
clusion in the pooled analysis there was no significant evidence of
statistical heterogeneity (Tau² = 0.00; I² = 0%; P for heterogeneity
= 0.41). On examination of the forest plot (see Figure 4), Eftekhari
2015 was also the only study where the point estimate of effect
favours placebo rather than probiotic (OR 0.54, 95% CI 0.22 to
1.32). We carried out a planned sensitivity analysis by removing
Eftekhari 2015 from the pooled analysis due to our judgement
on the risk of bias present in this study. The resulting estimate of
effect was an OR of 1.95 (95% CI 1.40 to 2.70; Z = 3.97; P <
0.001; 6 studies; 642 children; Tau² = 0.00; Chi² = 3.96; I² = 0%;
P for heterogeneity = 0.56; Analysis 1.6).
Figure 4. Forest plot of comparison: 1 Probiotics versus placebo, outcome: Improvement in pain 0 to 3
months’ postintervention.
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We were able to perform one subgroup analysis of improvement
in pain at zero to three months’ postintervention for 344 children
with irritable bowel syndrome only (Analysis 1.7). This included
four studies (Bausserman 2005; Francavilla 2010; Giannetti 2017;
Guandalini 2010). The OR for pain improvement at zero to three
months’ postintervention was 3.01 (95% CI 1.77 to 5.13; Z =
4.06; P < 0.001; Tau² = 0.06; Chi² = 3.77; I² = 21%; P for het-
erogeneity = 0.29), with a NNTB of four. Using GRADE, we
rated the quality of the evidence for this outcome as moderate,
downgrading it one level for imprecision, due to small numbers
of participants in included studies.
Only two studies (224 children) were eligible for inclusion in an
analysis of improvement in pain at three to six months’ postin-
tervention (Francavilla 2010; Saneian 2015), as most studies had
short follow-up periods. The OR for pain improvement at three
to six months’ postintervention was 1.94 (95% CI 1.10 to 3.43;
Z = 2.28; P = 0.02; Tau² = 0.00; Chi² = 0.41; I² = 0%; P for
heterogeneity = 0.52; Analysis 1.8), with a NNTB of seven. Using
GRADE, we rated the quality of the evidence for this outcome as
moderate, downgrading it one level due to imprecision.
Secondary outcomes
Results of individual studies
School performance
Gawronska 2007 assessed school absenteeism (included as a sec-
ondary outcome) as a dichotomous measure in 104 children (re-
ported in diaries) and found no difference between control and in-
tervention groups (P = 0.44). In Weizman 2016, the 101 included
children kept a school absence diary; postintervention there was
no significant difference in the number of days of absence between
the two groups (2.7 versus 1.9 days per four weeks, in the placebo
and the probiotic groups, respectively; P = 0.08). Kianifar 2015
assessed “functional changes”, which included disruption of social
activities, need to see a doctor, use of medications, and days of
absence from school, on a three-point Likert scale. The authors
reported that this measure improved significantly in the probiotic
group at four weeks’ postintervention (2.4 (SD 0.5) in the probi-
otic group, 1.9 (SD 0.4) in the placebo group; P < 0.001).
Social or psychological functioning
Kianifar 2015 included “disruption of social activities” as part
of their “functional changes” outcome, the results of which are
reported above.
Quality of daily life
In Guandalini 2010, caregivers of 59 children were asked to assess
family life disruption; the trial reported improvement in family life
disruption after six weeks in the intervention group (P < 0.001),
which was not present in the placebo group. Giannetti 2017 used
the Functional Disability Assessment to measure quality of life
(Claar 2006). An improved quality of life was reported by 46%
of children with irritable bowel syndrome after probiotics, versus
16% after placebo (P = 0.002). There was no difference in the
functional dyspepsia group.
Adverse events
Ten of the 13 studies included in this comparison reported that
the probiotic was well tolerated and that there were no adverse
events. In Saneian 2015, participants were specifically asked about
a checklist of adverse effects; the only symptom where there was a
significant difference was that of dry mouth, reported by 44% of
the intervention group and 23% of the control group. The studies
by Sabbi 2011 and Young 1997 were reported in abstracts and did
not report on adverse events.
Results of pooled analyses
No pooled analyses were possible.
Comparison 2: Fibreinterventions versus placebo
Four studies assessed the effects of fibre in various forms (Feldman
1985; Horvath 2013; Romano 2013; Shulman 2016).
Primary outcomes
Results of individual studies
Change in pain frequency
Feldman 1985 only reported figures for improvement in frequency
of pain at six weeks: 13 out of 26 children in the fibre cookie
group and 7 out of 26 children in the placebo group experienced
the outcome of improvement in pain following intervention (OR
2.71, 95% CI 0.85 to 8.64). No numerical data were given for the
other outcome of improved intensity of pain, which was simply
described as “not significant”.
In Shulman 2016, the authors reported a significant reduction in
pain frequency in the fibre group comparedwith the placebo group
using theNumerical Rating Scale (NRS-11) (McGrath 1996) after
the six-week intervention (P = 0.03).
Change in pain intensity
In Romano 2013, pain intensity was rated at baseline and at eight
weeks’ follow-up using theWong-Baker FACES Pain Rating Scale
(Wong 1988); whilst there was a greater decrease in intensity in
the intervention group, this was not statistically significant at the
P < 0.05 level.
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Improvement in pain
Horvath 2013 measured improvement in pain using the Faces
Pain Scale at four weeks (Bieri 1990): 23 out of 41 children in the
intervention arm and 20 out of 43 in the placebo arm experienced
the outcome of improvement in pain following intervention (OR
1.47, 95% CI 0.62 to 3.47).
Results of pooled analyses
See Summary of findings 2.
Change in pain frequency
We were not able to pool data for this outcome as it was either
not reported in these studies or there was no equivalent outcome
data.
Change in pain intensity
We were able to pool data fromRomano 2013 and Shulman 2016
in a meta-analysis for the outcome of change in pain intensity
at zero to three months’ postintervention. Both studies included
only children with irritable bowel syndrome. The SMD of effect
across the studies was -1.24 (95% CI -3.41 to 0.94; Z = 1.11; P
= 0.27; 2 studies; 135 children; Tau² = 2.38; Chi² = 28.91; I² =
97%; P for heterogeneity < 0.001; Analysis 2.1). The 95% CIs
for the point estimates of SMD in both studies did not overlap,
and very high statistical heterogeneity was detected according to
Chi² and I² tests. Romano 2013 used a tertiary clinic sample, and
Shulman 2016 used a mixed population recruited from primary
and specialist care. Using GRADE, we downgraded the quality of
evidence for this outcome by two levels to low, based on the high
levels of heterogeneity and the imprecision of the estimate.
Improvement in pain
We pooled data from Feldman 1985 and Horvath 2013 (136 chil-
dren) in a meta-analysis for the dichotomous outcome of improve-
ment in pain at zero to three months’ postintervention. The total
number of events in the meta-analysis was fewer than 70, with a
consequently imprecise estimate. The pooled OR was 1.83 (95%
CI 0.92 to 3.65; Z = 1.71; P = 0.09; 2 studies; 136 children; Tau²
= 0.00; Chi² = 0.69; I² = 0%; P for heterogeneity = 0.40; Analysis
2.2; Figure 5). Using GRADE, we rated the quality of evidence for
this outcome as low due to an unclear risk of bias in a number of
domains in the included studies and the small numbers of events
(fewer than 100).
Figure 5. Forest plot of comparison: 2 Fibre versus placebo, outcome: Improvement in pain 0 to 3 months’
postintervention.
Secondary outcomes
Results of individual studies
School performance
Horvath 2013 reported on the frequency of school absenteeism
in 84 children as described by parents (no specific measure re-
ported), and found no significant difference between intervention
and control groups (P = 0.56).
Social or psychological functioning
No studies reported data on this outcome.
Quality of daily life
Horvath 2013 reported no difference between intervention and
control groups in changes in daily activities in 84 children (no
measure reported) (P = 0.37). Shulman 2016 reported on health-
related quality of life using the Pediatric Quality of Life Generic
Core Scales (Varni 2015); no difference was found between the
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intervention and control groups on child report (P = 0.73) or
parent report (P = 0.99).
Adverse events
Horvath 2013 reported that no adverse events had occurred, al-
though four children in the intervention group complained of
symptom exacerbation compared to two in the placebo group;
Romano 2013 and Shulman 2016 also reported that no adverse
events had occurred. Feldman 1985 did not report adverse events.
Results of pooled analyses
No pooled analyses were possible.
Comparison 3: Low FODMAP diet versus normal diet
We found only one eligible study that examined the effect of a low
FODMAP diet. Chumpitazi 2015 compared two days of a low
FODMAP diet to two days of a typical American childhood diet
(TACD) in 33 children using a cross-over study design.
Primary outcomes
Results of individual studies
Change in pain frequency
Fewer episodes of abdominal pain per day occurred during the low
FODMAPdiet versus the control diet (P < 0.05), and compared to
baseline, children had fewer daily abdominal pain episodes during
the low FODMAP diet (P < 0.01), but more episodes during the
control diet (P < 0.01). Exact P values were not reported in the
paper.
Change in pain intensity
Median pain severity decreased on both diets in comparison to
baseline (low FODMAP diet P < 0.001, TACD P < 0.01; exact P
values not reported in the paper).
Improvement in pain
Eight children were categorised as responders (children who had
significant improvement in pain on the low FODMAP diet only),
15 as non-responders (children who did not have significant im-
provement on the low FODMAP diet or TACD), and 10 as
placebo responders (children who improved on both diets or only
on the TACD).
Results of pooled analyses
No pooled analyses were possible.
Secondary outcomes
Results of individual studies
No studies reported data on school performance, social or psycho-
logical functioning, or quality of daily life. No adverse effects were
reported.
Results of pooled analyses
No pooled analyses were possible.
Comparison 4: Fructose-restricted diet versus
normal diet
We found only one eligible study that examined the effect of a
fructose-restricted diet. In Wirth 2014, children with RAP for
more than three months were randomised to two weeks of a fruc-
tose-restricted diet or two weeks of a normal diet. Pain intensity
and frequency were measured at baseline and postintervention.
Primary outcomes
Results of individual studies
Change in pain frequency
InWirth 2014, 37 out of 50 (74%) of children in the intervention
group and 29 out of 51 (57%) in the control group reported a re-
duction in the number of pain episodes per week; both reductions
were described as ’statistically significant’.
Change in pain intensity
Wirth 2014 reported a significant decrease in pain intensity in the
intervention group after treatment (P < 0.001), and no difference
in pain intensity in the control group.
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Improvement in pain
No studies reported this outcome.
Results of pooled analyses
No pooled analyses were possible.
Secondary outcomes
No studies reported data on school performance, social or psycho-
logical functioning, or quality of daily life. Wirth 2014 did not
report on adverse effects.
Results of pooled analyses
No pooled analyses were possible.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Fibre versus placebo for recurrent abdominal pain in childhood
Patient or population: Children with recurrent abdominal pain
Settings: Mixed sett ings, predominant ly outpat ient gastroenterology clinics
Intervention: Fibre
Comparison: Placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo Fibre
Change in pain inten-
sity: 0 to 3 months’
postintervention
Pain intensity was mea-
sured using dif ferent
scales in the 2 in-
cluded studies: the
Wong Baker FACES
Pain Rating Scale,
Wong 1988, and the
Numerical Rat ing Scale
(von Baeyer 2009).
- The mean change in
pain intensity 0 to 3
months’ post interven-
t ion score in the in-
tervent ion groups was
1.24 SDs lower (3.41
lower to 0.94 higher)
- 135
(2 studies)
⊕⊕©©
Low2,3
-
Improvement in pain: 0
to 3 months’ postinter-
vention
Improvement in pain
was def ined and mea-
sured dif ferent ly in the
2 included studies: us-
ing a ‘‘stomach ache di-
ary’’ and the Faces Pain
391 per 10001 541 per 1000
(372 to 701)
OR 1.83
(0.92 to 3.65)
NNTB = 6.7
136
(2 studies)
⊕⊕©©
Low2,4
-
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Scale (Bieri 1990).
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; NNTB: number needed to treat for an addit ional benef icial outcome, based on the absolute risk reduct ion between the intervent ion and comparison
group probable outcomes; OR: odds rat io; SD: standard deviat ion.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1Assumed risk in control group is based on the mean outcome of the control group in the two included studies.
2Downgraded one level due to imprecision.
3Downgraded one level due to evidence of signif icant heterogeneity.
4Downgraded one level, as one study contained insuf f icient information regarding allocat ion concealment, outcome
assessment, and select ive report ing.
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D I S C U S S I O N
Summary of main results
We included 19 studies with a total of 1453 participants in this re-
view. With the exception of two studies, all studies assessed a treat-
ment armof probiotic or fibre-based interventions against placebo,
with an average treatment duration of six weeks. The remain-
ing two studies assessed a dietary intervention (low FODMAP
diet or fructose-restricted diet) against a normal control diet. This
update extends the evidence base in this area through the inclu-
sion of 15 new studies, along with four from the original review
(Huertas-Ceballos 2009); 10 pooled analyses were possible.
Evidence for probiotic interventions
Overall, the data in this review provided some evidence suggesting
that probiotics may be effective in the management of children
with RAP, based on the results of 13 studies. Trials used a range
of probiotic preparations: five used Lactobacillus rhamnosusGG in
slightly different preparations; three used Lactobacillus reuteri; two
used Bacillus coagulans with fructo-oligosaccharides; one used a
patented mixture; one used Lactobacillus plantarum; and one used
a mixture of Bifidobacterium species.
The majority of studies measured short-term outcomes at zero
to three months’ postintervention only. We found that probiotics
improved pain in the meta-analysis of seven probiotic trials at this
time point (OR 1.63, 95% CI 1.07 to 2.47; P = 0.02), with an
estimatedNNTBof eight,meaning that eight childrenwouldneed
to receive probiotics for one to experience improvement in pain in
this timescale. The planned sensitivity analysis removing studies
where the risk of bias for allocation concealment or blinding of
participants and personnel and/or blinding of outcome assessment
was high or unclear also found that children treatedwith probiotics
were more likely to experience an improvement in pain (OR 1.95,
95% CI 1.40 to 2.70; P < 0.001). The planned subgroup analysis
of children identified as having irritable bowel syndrome only at
the same time point resulted in a pooled OR of 3.01 (95% CI
1.77 to 5.13; P < 0.001), and an estimated NNTB of four.
For all children,we also found a reduction in pain frequency (SMD
-0.55, 95%CI -0.98 to -0.12; P = 0.012) and pain intensity (SMD
-0.50, 95% CI -0.85 to -0.15; P = 0.005), in those treated with
probiotics compared to placebo at zero to three months’ postin-
tervention.
We were able to perform only one pooled analysis of two studies
for outcomes at three to six months’ postintervention, for the
outcome of improvement in pain. The pooled OR was 1.94 (95%
CI 1.10 to 3.43; P = 0.023), with a NNTB of seven.
Using the GRADE approach, we rated the quality of the evidence
for all the improvement in pain outcomes as moderate, and the
quality of evidence for change in pain frequency and intensity as
low.
Evidence for fibre interventions
As in the previous version of this review (Huertas-Ceballos 2009),
the data in this analysis did not provide convincing evidence sug-
gesting that fibre supplements are effective in RAP, on the grounds
of a paucity of studies and a lack of moderate- or high-quality ev-
idence. We performed two meta-analyses, neither of which found
that fibre interventions were effective in improving pain.
Only two studies were eligible for inclusion in the meta-analysis
for the outcome of improvement of pain, with a pooled OR of
1.83 (95% CI 0.92 to 3.65; P = 0.09). Two different studies were
eligible for pooled analysis for the outcome of change in pain
intensity: the SMD of effect across the studies was -1.24 (95% CI
-3.41 to 0.94; P = 0.27); both studies included only children with
irritable bowel syndrome. Using GRADE, we assessed the quality
of the evidence for both outcomes as low.
Evidence for low FODMAP diet and fructose-
restricted diet
We found only one study each that examined the effects of a low
FODMAP diet and a fructose-restricted diet on pain in children
with RAP. We were therefore unable to perform any pooled anal-
yses for these two interventions.
Overall completeness and applicability of
evidence
There are some important considerations relating to the overall
completeness and applicability of the evidence from this study.
First, 11 out of 13 included probiotic studies measured outcomes
at zero to three months’ postintervention only, and most interven-
tions lasted only between four and six weeks. Only two included
studies measured outcomes at 12 weeks or more, although the
pooled analysis did find that improvement in pain was sustained
at this time point. Consequently, the evidence base for the longer-
term effectiveness of probiotics in the included studies needs to be
strengthened. Second, we were only able to perform one subgroup
analysis by category of RAP, which was for probiotics for chil-
dren with irritable bowel syndrome. However, the pooled analysis
suggested that a significant improvement in pain was experienced
by this group at short-term follow-up. Third, we were only able
to identify one study of low FODMAP diets and one of fruc-
tose-restricted diets eligible for inclusion. A number of RCTs of
low FODMAP diets have been conducted in adults with irritable
bowel syndrome (Nanayakkara 2016), but it appears that the area
of exclusion diets in children requires further research before ev-
idence-based recommendations regarding the use of these inter-
ventions can be made.
We would also like to highlight that few studies reported on our
secondary outcomes relating to school absence, social or psycho-
logical functioning, and quality of life, which represents a gap in
the completeness of the evidence base. These ’secondary’ outcomes
27Dietary interventions for recurrent abdominal pain in childhood (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
are important, as they are likely to indicate disability and to be
highly significant for the child and family.
Finally, we also note that the majority of studies took place in pae-
diatric gastroenterology clinics, with three taking place in mixed
settings and one in “primary care paediatrics”. We were therefore
unable to comment on any potential difference in outcome by
setting.
Quality of the evidence
The overall quality of evidence within this review as assessed by the
GRADE approach ranged from ’low’ to ’moderate’. We rated the
quality of the evidence for the three improvement in pain outcomes
in the probiotic and placebo comparison as moderate, downgrad-
ing for imprecision or heterogeneity. This means we judged that
further research is likely to have an important impact on our con-
fidence in the estimate of effect and may change the estimate. We
rated the quality of the evidence for the change in pain frequency
and intensity outcomes for the same comparison as being low due
to significant levels of heterogeneity and risk of bias introduced
by incomplete outcome data. This means that future research is
very likely to have an important impact on our confidence in the
estimate of effect and is likely to change the estimate.
In the case of the two pooled analyses comparing fibre interven-
tions to placebo, we rated the quality of the evidence as low due to
significant heterogeneity, imprecision, and an unclear risk of bias
in a number of domains in the included studies. Future research
in this area is therefore very likely to have an important impact on
our confidence in the estimate of effect and is likely to change the
estimate.
Potential biases in the review process
We conducted a comprehensive search of electronic databases,
but did not find sufficient studies to perform a formal assessment
of the likelihood of publication bias; consequently it is possible
that smaller studies may have been missed. Two review authors
independently carried out screening and ’Risk of bias’ assessments,
discussing any areas of disagreement with another review author.
Two review authors also checked data extraction. The methods
used were therefore unlikely to introduce bias.
Agreements and disagreements with other
studies or reviews
The findings of this review are in keeping with other systematic
reviews of dietary interventions in RAP. Horvath 2011, and more
recently Rutten 2015, reported that Lactobacillus rhamnosus GG
was associated with significantly more treatment responders than
placebo in theirmeta-analyses; the same authors found only incon-
clusive data regarding the effects of fibre supplements (Horvath
2012; Rutten 2015).
Issues for consideration
We rated the quality of the evidence provided by the included
studies as moderate or low (for probiotics) or low (for fibre). There
were additionally further issues for consideration. As discussed
above, the majority of studies were short term. We also noted
variety in the definition and scales used to assess improvement
in pain, meaning that this outcome does not reflect a universally
agreed clinically significant benchmark. It is therefore harder to
draw conclusions as to whether the reported improvements in
pain were clinically meaningful, although this is to some extent
a matter of judgement. The outcome of improvement in pain in
most included studies represented either a change to no pain or a
decrease by 50%,which could be argued to be clinically important.
This observation also applied to the assessment of other outcomes,
such as pain intensity and frequency.
As previously mentioned, many studies did not collect data on the
prespecified secondary outcomes of interest, such as school per-
formance or quality of daily life, meaning that the effect of dietary
interventions on these important outcomes was not measured and
that it was therefore not possible to conduct pooled analyses. Data
on these outcomes would also assist in determining the clinical
relevance of improvements in pain.
We performed no subgroup analyses by type or concentration
of probiotic, as we did not specify this in our protocol (Martin
2014b); each pooled analysis included studies using different
strains of probiotic, themost common being L rhamnosusGG and
L reuteri.
Finally, the majority of studies included children under the broad
umbrella of RAP and did not present results by RAP subtype.
Consequently, we were only able to perform one pooled analysis
for the subtype of irritable bowel syndrome for probiotic interven-
tions, although the eligible studies for the pooled analysis for pain
intensity in fibre interventions also included only children with
irritable bowel syndrome.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Overall, there is some evidence to suggest that probiotics may
be effective in the treatment of RAP, in terms of improving pain
in the shorter term. Clinicians may therefore consider probiotic
interventions as part of themanagement strategy for children with
RAP.However, we were unable to recommend the optimum strain
and dosage of probiotic based on this review.
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We did not find convincing evidence that fibre interventions were
effective in improving pain in children with RAP. The evidence
for other dietary interventions (e.g. low FODMAP or lactose-
or fructose-free diets) is also currently lacking, therefore we were
unable to make evidence-based recommendations regarding their
use in practice. For a holistic approach, the evidence from this
review regarding the effectiveness of dietary interventions should
also be considered in conjunction with evidence from the com-
panion Cochrane reviews covering pharmacological interventions,
Martin 2014a, and psychosocial interventions, Abbott 2017, for
RAP in childhood.
Implications for research
The evidence for the effectiveness of probiotics was based largely
on shorter-term outcomes. Further trials are required to assess
whether improvements in pain are maintained over the longer
term; these trials should also consider the importance of using val-
idated and consistent scales to measure pain and other outcomes.
Such studies could attempt to examine the effects of probiotics
on a wider range of outcomes important to children and their
parents, such as quality of life, school attendance, and disability.
Future research should also address the question of the optimal
strain and dosage schedule for probiotic interventions, as well as
consider the effectiveness of probiotics in different settings (the
majority of these studies were conducted in gastroenterology clin-
ics in Europe). It has been suggested that there are distinct subtypes
of RAP and that these could guide treatment choice (Drossman
2016). We therefore thought it important in this review to esti-
mate whether subtype predicted response to different treatment
modalities, however this needs further investigation to allow a tai-
lored approach to management.
In the case of fibre-based interventions and low FODMAP and
other exclusion diets, further high-quality RCTs involving larger
numbers of participants are needed to examine the effectiveness
of these interventions.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Asgarshirazi 2015
Methods 3-arm RCT with placebo control
Follow-up: 4 weeks
Participants Location: Iran
Setting: Paediatric gastroenterology outpatient clinic
Sample size: 120 children (40 probiotic, 40 peppermint oil, 40 control)
Sex: Not given for whole sample; for those analysed: 48 girls, 40 boys
Dropouts/withdrawals: 32 withdrawals, number analysed = 88
Diagnosis: Functional gastrointestinal disorders diagnosed using Rome III (Rasquin
2006)
Mean age: 7.44 (SD 2.44) years probiotic intervention, 7.42 (SD 2.49) years control
Interventions Intervention: Synbiotic Lactol tablet (150 million spores of Bacillus coagulans + fructo-
oligosaccharide) (Bioplus Life Sciences), 1 tablet, 3 x day
Control: Folic acid tablet (1 mg), 1 tablet, 2 x day
Third arm: Peppermint oil. Please see Pharmacological review, Martin 2014a, for this
comparison.
Outcomes 1. Pain severity (using Numerical Rating Scale 0-to-10)
2. Pain duration: minutes per day
3. Pain frequency: episodes per week
Notes Study dates: September 2012 to August 2014
Funding: Not stated
Declarations of interest: Not reported
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: Authors describe using block
randomisation (Asgarshirazi 2016 [pers
comm]), but no further detail given.
Allocation concealment (selection bias) Unclear risk Comment: Allocation concealment not
described.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: The nurse that carried out the
questionnaire was blinded. However, the
placebo regimen of folic acid tablets dif-
fered in timing and frequency to the inter-
vention regimen, which could have intro-
duced bias
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Asgarshirazi 2015 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: As above.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: All children accounted for,
however, 15 in control group and 11 in
probiotic group were excluded during trial
after randomisation and not analysed as
“they did not complete one-month drug
consumption (due to journey or lack of 2
weeks visit)”. No further explanation given
Selective reporting (reporting bias) Low risk Comment: All outcomes reported.
Other bias High risk The intervention and placebo groups dif-
fered at baseline, as duration of pain in the
intervention group was 67.05 mean min-
utes/day (SD ± 36.97) and the placebo
group was 53.4 mean minutes/day (SD ±
16.81)
Bausserman 2005
Methods RCT with placebo control
Follow-up: Post-treatment (6 weeks) follow-up
Participants Location: USA
Setting: Paediatric gastroenterology outpatient clinic
Sample size: 50 children (25 intervention, 25 control)
Sex: 10 boys, 40 girls
Dropouts/withdrawals: 6 withdrawals, 6 dropouts lost to follow-up, and 2 excluded
due to poor compliance; number analysed = 50
Diagnosis: Irritable bowel syndrome diagnosed using Rome II (Thompson 2000)
Mean age: 11.6 (SD 3.2) years intervention, 12.4 (SD 2.9) years control
Interventions Intervention:LactobacillusGG in capsule form in concentration of 1010 CFUof bacteria
with inulin, 1 capsule, 2 x day
Control: Inulin-only capsule identical in size, taste, and colour, 1 capsule, 2 x day
Outcomes 1. Improvement in pain, defined as number of responders with a decrease of 1 or
more points on a severity-of-symptom Likert scale, versus non-responders
2. Pain severity (Gastrointestinal Symptoms Rating Scale (Svedlund 1988))
Notes Study dates: July 2003 to June 2004
Funding: Wright State University School of Medicine seed grant
Declarations of interest: Not reported
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Bausserman 2005 (Continued)
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Comment: Computer-generated
randomisation.
Allocation concealment (selection bias) Low risk Comment: Pharmacist dispensed drugs.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Comment: Double-blind with placebo
control.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: Double-blind with placebo
control.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: 2 children in the interven-
tion group were removed postrandomisa-
tion due to poor compliance and were
not analysed. 3 lost to follow-up in each
arm and not analysed. 6 withdrew from
the study before data were collected but
postrandomisation and were therefore not
analysed
Selective reporting (reporting bias) Low risk Comment:All outcomesmentioned are re-
ported.
Other bias Low risk Comment:Aside fromoutcomedata, over-
all well reported.
Chumpitazi 2015
Methods Cross-over RCT with ’typical diet’ control
Follow-up: Postintervention at 2 days
Participants Location: USA
Setting: Paediatric gastroenterology outpatient clinic and self referral via community
advertisements
Sample size: 34 children
Sex: 22 girls, 12 boys
Dropouts/withdrawals: 1 excluded postrandomisation; 33 analysed
Diagnosis: Irritable bowel syndrome diagnosed using Rome III (Rasquin 2006)
Mean age: 11.5 (SD 3) years
38Dietary interventions for recurrent abdominal pain in childhood (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Chumpitazi 2015 (Continued)
Interventions Intervention: Low FODMAP (fermentable oligosaccharides, disaccharides, monosac-
charides and polyols) diet containing 0.15 g/kg/day (maximum 9 g/day) of FODMAPs.
2-day diet, preprepared and delivered to participants
Control:Typical American childhood diet (TACD) containing 0.7 g/kg/day (maximum
50 g/day) of FODMAPs. 2-day diet, preprepared and delivered to participants
Washout: 5-day washout period in between.
Outcomes 1. Improvement in pain, defined as participants who had a ≥ 50% decrease in the
number of daily abdominal pain episodes
2. Pain severity (pain diary using a 1-to-10 Likert scale)
3. Pain frequency (episodes per day recorded in diary)
Notes Study dates: September 2011 to December 2013
Funding:North American Society for Pediatric Gastroenterology, Hepatology and Nu-
trition Foundation/Nestlé Nutrition Career Development Award and US National In-
stitutes of Health (NIH) K23 DK101688 (BPC)
Declarations of interest: Bruno Chumpitazi received funding from the NIH, QOL
Medical Inc., and is a consultant for Mead Johnson Nutrition. Robert Shulman received
funding from the NIH and Mead Johnson Nutrition and is a consultant for Nutrinia
Ltd. and Gerson Lehrman Group. James Versalovic received funding from the NIH and
BioGaia AB. The remaining authors do not have personal interests to disclose
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Comment: Computer-generated block
randomisation.
Allocation concealment (selection bias) Low risk Comment: Randomisation handled by ex-
ternal research dietician.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: Double-blind but unclear
whether both diets were delivered in iden-
tical containers or whether there were other
ways for participants to guess the allocation
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: Double-blind but unclear
whether both diets were delivered in iden-
tical containers or whether there were other
ways for participants to guess the allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: All participants accounted for.
Selective reporting (reporting bias) Low risk Comment: All stated outcomes reported.
Other bias Low risk Comment: Well-conducted study.
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Eftekhari 2015
Methods RCT with placebo control
Follow-up: 4 weeks postintervention (at 8 weeks)
Participants Location: Iran
Setting: Paediatric gastroenterology outpatient clinic
Sample size: 80 children
Sex: 40 girls, 40 boys
Dropouts/withdrawals: Not discussed/no information given
Diagnosis: RAP diagnosed using Rome III (Rasquin 2006)
Mean age: 6.26 (SD 2.10) years intervention, 6.26 (SD 2.10) years control
Interventions Intervention: Lactobacillus reuteri 5 drops per day orally equivalent to 108CFU for 4
weeks
Control: Placebo (no further details given)
Outcomes 1. Improvement in pain, defined as percentage with no pain
2. Pain severity using Wong-Baker FACES Pain Rating Scale (Wong 1988)
3. Pain frequency using Wong-Baker FACES Pain Rating Scale (Wong 1988)
Notes Study dates: 2012 to 2013 (14 months)
Funding: Zanjan University of Medical Sciences
Declarations of interest: Not mentioned
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: Only detail given is: ran-
domised allocation (computer registration)
Allocation concealment (selection bias) Unclear risk Comment: Only detail given is: ran-
domised allocation (computer registration)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Comment: Double-blind study.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: Double-blind study.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: Does not mention loss to fol-
low-up or withdrawals.
Selective reporting (reporting bias) Low risk Comment: Reports all outcomes men-
tioned.
Other bias Low risk Comment:No other major sources of bias.
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Feldman 1985
Methods RCT with placebo control
Follow-up: 6 weeks
Participants Location: Canada
Setting: Private GP practices and community paediatric clinics
Sample size: 52 children (26 intervention, 26 control)
Sex: 17 boys, 35 girls
Dropouts/withdrawals: None reported
Diagnosis: At least 1 attack per week of unexplained abdominal pain over 2 months
Mean age: 9.31 (SD 3.2) years intervention, 9.44 (SD 2.9) years control
Interventions Intervention: Fibre cookie (5 g corn per cookie), twice a day
Control: Placebo cookie, twice a day, identically wrapped to the intervention cookie
(cookies tasted different but believed to be no cross-over)
Outcomes 1. Frequency of pain (stomachache diary)
2. Pain intensity (stomachache diary)
Notes Study dates: Not given
Funder: Not reported
Declarations of interest: Not reported
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Comment: Computer-generated random
number system.
Allocation concealment (selection bias) Unclear risk Comment: Insufficient information re-
ported.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Comment: Cookies wrapped identically.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: Parents, children, and clini-
cians blinded to allocation.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: Have complete outcome data
on all included children.
Selective reporting (reporting bias) Unclear risk Comment: Insufficient information. Does
not report all numerical data
Other bias Low risk Comment:No other major sources of bias.
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Francavilla 2010
Methods RCT with placebo control
Follow-up: 8 weeks and 16 weeks
Participants Location: Italy
Setting: Primary care paediatric practices
Sample size: 141 children (71 intervention, 70 control)
Sex: Not given for whole sample
Dropouts/withdrawals: 4 dropped out (2 from intervention, 2 from control) and 1
withdrew (from control)
Diagnosis: Irritable bowel syndrome or functional abdominal pain diagnosed using
Rome II (Thompson 2000)
Mean age: 6.5 (SD 2.1) years intervention, 6.3 (SD 2.0) years control
Interventions Intervention: Oral Lactobacillus GG (3 x 1010 CFU), twice per day for 8 weeks
Control: Identical-looking/tasting placebo twice per day for 8 weeks
Outcomes 1. Pain episodes and severity (visual analogue scale and Faces Pain Scale combined
(McGrath 1996))
2. Treatment success (as above; success defined as 50% reduction in baseline pain
episodes and intensity)
Notes Study dates: 2004 to 2008
Funder: Not reported
Declarations of interest: Not reported
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Comment: Computer-generated ran-
domisation list with permuted block design
Allocation concealment (selection bias) Low risk Comment: Enrolled children entered se-
quentially to computer-generated ran-
domisation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Comment: Identical-looking/tasting
placebo. Group assignment was concealed
from participants and investigators
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: Double-blind.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: 4 children dropped out, but 2
each from control and intervention group.
Analysis based on 137 children, not 141
allocated
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Francavilla 2010 (Continued)
Selective reporting (reporting bias) Low risk Comment: All outcomes reported.
Other bias Low risk Comment: Well-conducted and reported
study.
Gawronska 2007
Methods RCT with placebo control
Follow-up: 4 weeks
Participants Location: Poland
Setting: University department of paediatric gastroenterology
Sample size: 104 children (52 intervention, 52 control)
Sex: 48 boys, 56 girls
Dropouts/withdrawals: None
Diagnosis: Functional dyspepsia, irritable bowel syndrome, or functional abdominal
pain diagnosed using Rome II (Thompson 2000)
Mean age: 11.9 (SD 3.0) years intervention, 11.2 (SD 2.7) years control
Interventions Intervention: Lactobacillus rhamnosusGG (3 x 109 CFU) capsules twice daily orally for
4 weeks
Control: Identical placebo, twice daily orally for 4 weeks
Outcomes 1. Improvement in pain (treatment success) (Faces Pain Scale (Bieri 1990))
2. Pain intensity and frequency (Faces Pain Scale (Bieri 1990))
3. Medication for abdominal pain (diary)
4. School absenteeism due to abdominal pain (diary)
Notes Study dates: October 2003 to May 2006
Funder:Medical University of Warsaw
Declarations of interest: Not reported
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Comment: Computer-generated list with
permutated block design.
Allocation concealment (selection bias) Low risk Comment: Adequate methods for alloca-
tion sequence concealment.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Comment: All blinded to assignment.
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Gawronska 2007 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: All blinded to assignment.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: All participants accounted for.
Selective reporting (reporting bias) Low risk Comment: All outcomes reported.
Other bias Low risk Comment: Well-conducted and reported
study.
Giannetti 2017
Methods Cross-over RCT with placebo control
Follow-up: 6 weeks
Participants Location: Italy
Setting: Tertiary paediatric clinic
Sample size: 78 children
Sex: 32 boys, 41 girls (of those analysed)
Dropouts/withdrawals: 1 exclusion, 4 lost to follow-up during washout
Diagnosis: Irritable bowel syndrome or functional dyspepsia diagnosed using Rome III
(Rasquin 2006)
Mean age: Irritable bowel syndrome 11.2 (range 8 to 17.9) years, functional dyspepsia
11.6 (range 8 to 16.6) years
Interventions Intervention: 1 sachet per day of amixture of 3Bifidobacterium species (namely, 3 billion
of B longum BB536, 1 billion of B infantis M-63, 1 billion of B breve M-16V) for 6
weeks, followed by a 2-week washout period
Control: Identical placebo
Outcomes 1. Improvement in pain defined as being pain-free using validated questionnaire
(Walker 2006)
2. Pain frequency measured using validated questionnaire (Walker 2006)
3. Functional Disability Inventory (Claar 2006)
Notes Study dates: January 2014 to December 2014
Funder: None reported
Declarations of interest: The authors declare no conflicts of interest.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Comment: Computer-generated
randomisation.
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Giannetti 2017 (Continued)
Allocation concealment (selection bias) Low risk Comment: Independent physician in-
volved in the randomisation.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Comment: All blinded to assignment.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: All blinded to assignment.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: All participants accounted for
and intention-to-treat analysis carried out
Selective reporting (reporting bias) Low risk Comment: All outcomes reported, but un-
able to obtain raw data for pain frequency
outcome from authors as they did not re-
spond to our written request (Giannetti
2017).
Other bias Low risk Comment: Overall a well-conducted trial
Guandalini 2010
Methods Cross-over RCT with placebo control
Follow-up: 6 weeks
Participants Location: Italy and India
Setting: Paediatric tertiary care centres
Sample size: 67 (cross-over trial) enrolled, 59 completed
Sex: 31 boys, 28 girls (of those completing study)
Dropouts/withdrawals: 8 children did not complete the study, 4 from the placebo arm
and 4 from the study arm. Reasons for dropouts were inability/unwillingness to complete
questionnaires (6 children) and dislike of the preparation given (1 each from study and
placebo group)
Diagnosis: Irritable bowel syndrome diagnosed using Rome II (Thompson 2000)
Mean age: 12.5 (SD not given; range 5 to 18) years
Interventions Intervention: Patented probiotic preparation VSL#3 (contains live, freeze-dried lactic
acid bacteria, at a total concentration of 450 billion lactic acid bacteria per sachet,
comprising 8 different strains: Bifidobacterium breve, B longum, B infantis, Lactobacillus
acidophilus, L plantarum, L casei, L bulgaris, and Streptococcus thermophiles). 1 sachet once
per day for children aged 4 to 11 years and twice a day for children aged 12 to 18 years
for 6 weeks
Control: Identical-looking/tasting placebo taken as above
Outcomes 1. Improvement in pain (Subject’s Global Assessment of Relief Child version
(SGARC) (Muller-Lissner 2003))
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Guandalini 2010 (Continued)
2. Pain frequency and intensity (measure not described)
3. Disruption of daily life (measure not described)
Notes Study dates: Not given
Funder: Funded by locally available grants. There was no industry support except for
providing product and placebo
Declarations of interest: Not reported
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Comment: Computer-generated
randomisation.
Allocation concealment (selection bias) Low risk Comment: Separate centre in Chicago, IL,
USA managed the data and allocations
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Comment: Double-blind, identical-look-
ing/tasting placebo.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: Self reported outcomes, but
blinded to treatment group.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: All participants accounted for.
Selective reporting (reporting bias) Unclear risk Comment: Comparisons made pre/post
and not between intervention and control
at week 6
Other bias Low risk Comment:No other major sources of bias
identified.
Horvath 2013
Methods RCT with placebo control
Follow-up: 4 weeks
Participants Location: Poland
Setting: University department of paediatric gastroenterology
Sample size: 84 children (41 intervention, 43 control)
Sex: 42 boys, 42 girls
Dropouts/withdrawals: 7 lost to follow-up, 3 withdrawals, 2 protocol violations (all
excluded from analysis)
Diagnosis:Abdominal pain-related functional gastrointestinal disorders diagnosed using
Rome III (Rasquin 2006)
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Horvath 2013 (Continued)
Mean age: 11.6 (SD 3.0) years intervention, 11.3 (SD 2.5) years control
Interventions Intervention: GNN (glucomannan) polysaccharide of 1,4-D-glucose and D-mannose,
2.52 g per day in 2 doses from sachets dissolved in 125 mL of fluid consumed twice a
day (morning and evening) for 4 weeks
Control: Placebo of maltodextrin at same dosage for 4 weeks
Outcomes 1. Improvement in pain (no pain or decrease of 2 or more points on Faces Pain
Scale-Revised (Bieri 1990))
2. Subjective assessment of pain frequency, abdominal cramps and bloating, nausea,
changes in stools (measure not described)
3. School absenteeism, changes in daily activities, rescue therapy, and adverse effects
(measure not described)
Notes Study dates: January 2009 to October 2011
Funder: Not stated
Declarations of interest: Not reported
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Comment: Computer-generated block
randomisation.
Allocation concealment (selection bias) Low risk Comment: Adequate methods described,
and sequence was concealed until all data
were analysed
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Comment: Double-blind.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: Double-blind.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: Very basic data reported.
Selective reporting (reporting bias) Low risk Comment: All outcomes discussed.
Other bias Low risk Comment: Fairly well-reported study.
47Dietary interventions for recurrent abdominal pain in childhood (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Kianifar 2015
Methods RCT with placebo control
Follow-up: 4 weeks, immediately postintervention
Participants Location: Iran
Setting: University department of paediatric gastroenterology
Sample size: 60 children (30 intervention, 30 control)
Sex: 27 boys, 25 girls (of those analysed, not given for all included)
Dropouts/withdrawals: 5 excluded due to lack of follow-up (no breakdown by inter-
vention group given); 3 excluded as took antibiotics during study period
Diagnosis: Irritable bowel syndrome diagnosed using Rome III (Rasquin 2006)
Mean age: 7.3 (SD 0.5) years intervention, 6.8 (SD 0.4) years control
Interventions Intervention: Lactobacillus rhamnosus GG with a concentration of 1 × 1010 CFU/mL
bacteria, 1 capsule twice per day for 4 weeks
Control: Identical placebo containing inulin at same dosage for 4 weeks
Outcomes 1. Pain severity using 5-point Likert scale
2. Functional changes (disruption of social activities, days of absence from school)
rated using 3-point Likert scale
Notes Study dates: August 2012 to September 2012
Funder:Mashhad University of Medical Sciences, Iran
Declarations of interest: Authors declare no conflicts of interest.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Comment: Randomisation using com-
puter-generated list with permutated block
design
Allocation concealment (selection bias) Low risk Comment: Randomisation using com-
puter-generated list with permutated block
design
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Comment: Double-blind with identical
placebo.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: Double-blind with identical
placebo.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment:Numbers lost to follow-up not
given by group.
Selective reporting (reporting bias) Low risk Comment: All outcomes reported.
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Kianifar 2015 (Continued)
Other bias Low risk Comment:No other major sources of bias
identified.
Romano 2010
Methods RCT with placebo control
Follow-up: 8 weeks
Participants Location: Italy
Setting: University department of paediatrics
Sample size: 56 children (30 intervention, 26 control)
Sex: 25 boys, 31 girls
Dropouts/withdrawals: 4 children “lost to completion” (see below)
Diagnosis: Functional abdominal pain diagnosed using Rome III (Rasquin 2006)
Mean age: 10.2 (SD 2.5) years intervention, 9.6 (SD 0.4) years control
Interventions Intervention: Oral supplementation with Lactobacillus reuteri DSM 17938, 108 CFU,
twice daily for 4 weeks
Control: Identical placebo, twice daily for 4 weeks
Outcomes 1. Pain intensity (Wong-Baker FACES Pain Rating Scale; in diary, filled in daily
(Wong 1988))
2. Pain frequency of functional abdominal pain symptoms (Wong-Baker FACES
Pain Rating Scale; in diary, filled in daily (Wong 1988))
Notes Study dates: Not given
Funder: Not stated
Declarations of interest: Not reported
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Comment: Randomisation was based on
a computer-generated list, which was re-
tained by the dispensing pharmacist at each
centre to ensure allocation concealment
Allocation concealment (selection bias) Low risk Comment: See above.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Comment: Double-blind.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: Parent/child reporting, but
they are unaware of which treatment they
had been allocated to
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Romano 2010 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: 4 children “lost to completion”
due to non-compliance postrandomisation
and were not analysed. Unclear if excluded
or lost to follow-up
Selective reporting (reporting bias) Low risk Comment: All outcomes reported. Au-
thors supplied raw data for pain frequency
and intensity outcomes on review authors’
request (Romano 2014 [pers comm]), as
these were shown in charts only in paper.
Other bias Low risk Comment: No other sources of bias iden-
tified.
Romano 2013
Methods RCT with placebo control
Follow-up: 8 weeks
Participants Location: Italy
Setting: University department of paediatric gastroenterology
Sample size: 60 children (30 intervention, 30 control)
Sex: 23 boys, 37 girls
Dropouts/withdrawals: None
Diagnosis: Irritable bowel syndrome, diagnosed using Rome III (Rasquin 2006)
Mean age: 12.3 (SD 2.0) years intervention, 13.1 (SD 1.5) years control
Interventions Intervention: Partially hydrolysed guar gum (PHGG - vegetal, water-soluble, non-vis-
cous, gelling dietary fibre), 5 g/day hidden in 50 mL fruit juice for 4 weeks
Control: Placebo of 50 mL fruit juice per day for 4 weeks
Outcomes 1. Pain intensity (Wong-Baker FACES Pain Rating Scale (Wong 1988))
2. Other symptoms of irritable bowel syndrome (Bristol Stool Scale (Lewis 1997),
Birmingham IBS Symptom Questionnaire (Roalfe 2008))
3. Safety and compliance: recorded adverse events
Notes Study dates: November 2010 to May 2011
Funder: Not stated
Declarations of interest: Not reported
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Comment: Randomisation was based on a
computer-generated list.
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Romano 2013 (Continued)
Allocation concealment (selection bias) Unclear risk Comment: Insufficient information to
judge
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Comment: Placebo was used, so partici-
pants blinded; states that investigators were
also blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: As above
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: All participants accounted for
and analysed.
Selective reporting (reporting bias) Low risk Comment: All outcomes reported.
Other bias Low risk Comment:No other major sources of bias
identified.
Sabbi 2011
Methods RCT with placebo control
Follow-up: 10 weeks
Participants Location: Italy
Setting: Not stated
Sample size: 61 children
Sex: Not stated
Dropouts/withdrawals: Not stated
Diagnosis: Functional abdominal pain
Mean age: Not stated
Interventions Intervention: Lactobacillus rhamnosus GG (no further details given) for 6 weeks
Control: Placebo (no further details given)
Outcomes 1. Pain frequency (measure not given)
2. Pain intensity (measure not given)
Notes Study dates: Not stated
Funder: Not stated
Declarations of interest: Authors report no conflicts of interest. This was an abstract.
We wrote to the author for further details but received no response (Sabbi 2011).
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
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Sabbi 2011 (Continued)
Random sequence generation (selection
bias)
Unclear risk Comment: Insufficient information to
judge.
Allocation concealment (selection bias) Unclear risk Comment: Insufficient information to
judge.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Comment: Double-blind with placebo
control.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: Double-blind with placebo
control, but unclear how outcome was as-
sessed
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: Insufficient information to
judge.
Selective reporting (reporting bias) Unclear risk Comment: Insufficient information to
judge.
Other bias Unclear risk Comment: Insufficient information to
judge.
Saneian 2015
Methods RCT with placebo control
Follow-up: 12 weeks
Participants Location: Iran
Setting: Outpatient tertiary clinic of paediatric gastroenterology
Sample size: 88 children (45 intervention, 43 control)
Sex: 49 boys, 39 girls
Dropouts/withdrawals: 21 withdrew (9 intervention, 12 control); 5 discontinued (all
from intervention); 1 excluded due to antibiotic use; 9 lost to follow-up (5 intervention,
4 control). All were excluded from analysis
Diagnosis: Functional abdominal pain diagnosed using Rome III (Rasquin 2006)
Mean age: 9.0 (SD 2.2) years intervention, 8.5 (SD 2.2) years control
Interventions Intervention: Synbiotic tablets twice daily for a duration of 4 weeks, consisting of the
probiotic Bacillus coagulans plus fructo-oligosaccharide (100 mg)
Control: Placebo tablets
Outcomes Measured at 4 and 12 weeks
1. Improvement in pain defined as at least 2-point reduction in or “no pain” after
medication using Wong-Baker FACES Pain Rating Scale (Wong 1988)
2. Clinical Global Impression Severity and Improvement scales (CGI-S; CGI-I)
(Guy 1976), physician-rated scales of the global severity of the illness and improvement
by the treatment, respectively
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Saneian 2015 (Continued)
3. Reported on adverse effects (intervention group (44.4%) experienced more dry
mouth compared to control (23.2%))
Notes Study dates: February 2013 to December 2013
Funder: Isfahan University of Medical Sciences
Declarations of interest: Not reported
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Comment: Computer-generated block
randomisation.
Allocation concealment (selection bias) Low risk Comment: Bottles coded by pharmacist,
allocation concealed.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Comment: Attending physician, partici-
pants, and outcome assessor were unaware
of the drug codes until the end of the study
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: Outcome assessor blinded.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment:Paper reports that an intention-
to-treat analysis was used, but they did not
analyse everyone that had been randomised
to each group: 14 in the intervention group
and 11 in the control group discontinued
medication and were not analysed
Selective reporting (reporting bias) Low risk Comment: Authors report all stated out-
comes, but they do not present raw scores
for the continuous data, only the change in
score
Other bias Low risk Comment:No other major sources of bias.
Shulman 2016
Methods RCT with placebo control
Follow-up: 6 weeks immediately postintervention
Participants Location: USA
Setting: Paediatric healthcare network, including both primary and tertiary care
Sample size: 103 children (51 intervention, 52 control)
Sex: 55 boys, 48 girls
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Shulman 2016 (Continued)
Dropouts/withdrawals: 15 withdrew (12 intervention, 3 control); 1 excluded from
intervention group; 3 lost to follow-up (1 intervention, 2 control). All were excluded
from analysis. 84 analysed
Diagnosis: Irritable bowel syndrome diagnosed using Rome III (Rasquin 2006)
Mean age: 13.1 (SD 0.4) years intervention, 13.5 (SD 0.4) years control
Interventions Intervention: Psyllium fibre. Children 7 to 11 years of age received 6 g, children 12 to
18 years of age received 12 g
Control: Placebo tablets containing maltodextrin; single daily dose in identical packets
Outcomes 1. Pain severity using Numerical Rating Scale (NRS-11) (von Baeyer 2009)
2. Pain frequency using Numerical Rating Scale (NRS-11) (von Baeyer 2009)
3. Health-related quality of life using Pediatric Quality of Life Generic Core Scales
(Varni 2015)
Notes Study dates: January 2009 to March 2014
Funder: National Institutes of Health, the Daffy’s Foundation
Declarations of interest: Authors state no conflicts of interest.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Comment: Block randomisation
described.
Allocation concealment (selection bias) Low risk Comment: Allocation concealment de-
scribed.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Comment: Double-blind study.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: Double-blind study.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: 15 withdrew (12 intervention,
3 control); 1 excluded from intervention
group; 3 lost to follow-up (1 intervention,
2 control). All were excluded from analysis
Selective reporting (reporting bias) Low risk Comment: All outcomes reported. Au-
thors supplied raw data for pain frequency
and intensity outcomes on review authors’
request (Shulman 2016), as these were
shown in charts only in paper.
Other bias Low risk Comment:No other major sources of bias.
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Weizman 2016
Methods RCT with placebo control
Follow-up: 8 weeks
Participants Location: Israel
Setting: Paediatric outpatient clinics and community childcare centres
Sample size: 101 children (52 intervention, 49 control)
Sex: 53 boys, 40 girls (of those analysed)
Dropouts/withdrawals: 8 excluded due to poor compliance (5 in intervention, 3 in
control group); 93 analysed
Diagnosis: Functional gastrointestinal disorder diagnosed using Rome III (Rasquin
2006)
Mean age: 12.2 (SD 2.8) years intervention, 11.7 (SD 3.2) years control
Interventions Intervention: Lactobacillus reuteri DSM 17938 108 CFU/day once a day as chewable
tablets for 4 weeks
Control: Identical placebo tablets once a day for 4 weeks
Outcomes 1. Pain severity using Hicks Faces Pain Scale-Revised (Hicks 2001)
2. Pain frequency using Hicks Faces Pain Scale-Revised (Hicks 2001)
3. School absenteeism: self report diary
Notes Study dates: March 2011 to October 2013
Funder: Study products supplied by BioGaia. No other funding source declared
Declarations of interest: ZW has served as a speaker for BioGaia. Other authors state
no conflicts of interest
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Comment:Adequatemethods of randomi-
sation described.
Allocation concealment (selection bias) Low risk Comment: Allocation concealment was
ensured by an independent person
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Comment: Double-blind design.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: Double-blind design.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: 8 children (5 control, 3 inter-
vention) excluded due to “poor compliance
and violation of the protocol”, but states
was an intention-to-treat analysis; as these
children are not included in the analysis,
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Weizman 2016 (Continued)
this was not intention-to-treat
Selective reporting (reporting bias) Low risk Comment: All outcomes reported.
Other bias Low risk Comment:No other major sources of bias
identified.
Wirth 2014
Methods RCT with standard/unchanged diet as control
Follow-up: 2 weeks
Participants Location: Germany
Setting: Not specified
Sample size: 103 children (51 intervention, 52 control)
Sex: 41 boys, 62 girls
Dropouts/withdrawals: 1 excluded and 6 lost to follow-up in each arm
Diagnosis: Recurrent abdominal pain for more than 3 months and otherwise healthy
condition determined by a standardised evaluation procedure. Pain frequency had to be
at least 3 times per week. Does not mention using Rome criteria. Exclusion criteria were
positive lactose hydrogen breath test
Mean age: Not given. Median age 8.8 years (range 3.4 to 16.4 years)
Interventions Intervention: Fructose-restricted diet (fully described in paper) for 2 weeks
Control: Standard diet, no dietary changes
Outcomes 1. Pain intensity (as measured by questionnaire, no reference given)
2. Pain frequency (as above)
3. ”secondary symptoms score” (SSS) was created from 8 parameters (nausea,
vomiting, fatigue, sleep disturbance, headache, dizziness, anorexia, and use of pain
relievers). No reference given.
Notes Study dates: Not given
Funder: No details given
Declarations of interest: The authors declare no conflicts of interest.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: No details given of process.
Allocation concealment (selection bias) Unclear risk Comment: No details given of process.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Comment: Participants could not be
blinded as standard diet was the compara-
tor
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Wirth 2014 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Comment: As above, plus outcomes were
participant-reported, so subject to bias
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: No details given regarding loss
to follow-up.
Selective reporting (reporting bias) Low risk Comment: All outcomes reported.
Other bias Unclear risk Comment:Did not appear to use validated
tools. No details given regarding adherence
Young 1997
Methods Cross-over RCT with placebo control
Follow-up: 4 weeks
Participants Location: USA
Setting: Not specified
Sample size: 11 children
Sex: Not given
Dropouts/withdrawals: Not given
Diagnosis: Chronic recurrent abdominal pain of childhood
Mean age: Not given. Reported as “school age”.
Interventions Intervention: Lactobacillus plantarum 299V (LP299V)
Control: Placebo
Outcomes Pain severity as measured by index designed for the study (no reference given)
Notes Study dates: Not given
Funder: No details given
Declarations of interest: Not given. This was an abstract. The authors of the previous
Cochrane review, Huertas-Ceballos 2009, wrote to the author, but there were no further
details available
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: Insufficient information to
judge.
Allocation concealment (selection bias) Unclear risk Comment: Insufficient information to
judge.
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Young 1997 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Comment: Double-blinded study with
placebo.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: Double-blind study with
placebo.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: Insufficient information to
judge.
Selective reporting (reporting bias) Unclear risk Comment: Insufficient information to
judge.
Other bias Unclear risk Comment: Insufficient information to
judge.
CFU: colony-forming units.
DSM: Deutsche Sammhatg von Mikroorganismen (classification system of micro-organisms).
GP: general practice.
RAP: recurrent abdominal pain.
RCT: randomised controlled trial.
SD: standard deviation.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Agah 2015 Ineligible study design (not randomised)
Christensen 1982 Ineligible study design (not randomised)
Chumpitazi 2014 Ineligible comparator
Dearlove 1983 Ineligible study design (not randomised)
Edwards 1991 Ineligible comparator
Lebenthal 1981 Ineligible study design (not randomised)
58Dietary interventions for recurrent abdominal pain in childhood (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Characteristics of studies awaiting assessment [ordered by study ID]
Jarocka-Cyrta 2002
Methods Double-blind, placebo-controlled trial
Participants Children over 6 years of age with recurrent abdominal pain
Interventions Not stated
Outcomes Not stated
Notes No abstract or full text available as yet for this study, and no contact details available for the author
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D A T A A N D A N A L Y S E S
Comparison 1. Probiotics versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Change in pain frequency: 0 to
3 months’ postintervention
6 523 Std. Mean Difference (IV, Random, 95% CI) -0.55 [-0.98, -0.12]
2 Change in pain frequency: 0 to
3 months’ postintervention.
Sensitivity analysis
4 389 Std. Mean Difference (IV, Random, 95% CI) -0.54 [-0.94, -0.14]
3 Change in pain intensity: 0 to 3
months’ postintervention
7 575 Std. Mean Difference (IV, Random, 95% CI) -0.50 [-0.85, -0.15]
4 Change in pain intensity: 0 to
3 months’ postintervention.
Sensitivity analysis
5 441 Std. Mean Difference (IV, Random, 95% CI) -0.68 [-1.05, -0.30]
5 Improvement in pain: 0 to 3
months’ postintervention
7 722 Odds Ratio (M-H, Random, 95% CI) 1.63 [1.07, 2.47]
6 Improvement in pain: 0 to 3
months’ postintervention.
Sensitivity analysis
6 642 Odds Ratio (M-H, Random, 95% CI) 1.95 [1.40, 2.70]
7 Improvement in pain: 0 to 3
months’ postintervention.
Subgroup analysis (irritable
bowel syndrome)
4 344 Odds Ratio (M-H, Random, 95% CI) 3.01 [1.77, 5.13]
8 Improvement in pain: 3 to 6
months’ postintervention
2 224 Odds Ratio (M-H, Random, 95% CI) 1.94 [1.10, 3.43]
Comparison 2. Fibre versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Change in pain intensity: 0 to 3
months’ postintervention
2 135 Std. Mean Difference (IV, Random, 95% CI) -1.24 [-3.41, 0.94]
2 Improvement in pain: 0 to 3
months’ postintervention
2 136 Odds Ratio (M-H, Random, 95% CI) 1.83 [0.92, 3.65]
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Analysis 1.1. Comparison 1 Probiotics versus placebo, Outcome 1 Change in pain frequency: 0 to 3 months’
postintervention.
Review: Dietary interventions for recurrent abdominal pain in childhood
Comparison: 1 Probiotics versus placebo
Outcome: 1 Change in pain frequency: 0 to 3 months’ postintervention
Study or subgroup Probiotic Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Asgarshirazi 2015 29 2.14 (0.87) 25 3.4 (1.41) 15.0 % -1.08 [ -1.65, -0.50 ]
Eftekhari 2015 40 0.7 (0.75) 40 0.53 (0.59) 16.9 % 0.25 [ -0.19, 0.69 ]
Francavilla 2010 67 1.1 (0.8) 69 2.2 (1.2) 17.9 % -1.07 [ -1.43, -0.71 ]
Gawronska 2007 52 2.2 (1.7) 52 2.6 (1.4) 17.6 % -0.25 [ -0.64, 0.13 ]
Romano 2010 30 2.12 (0.6) 26 2.6 (0.5) 15.3 % -0.85 [ -1.40, -0.30 ]
Weizman 2016 47 3.4 (2.6) 46 4.4 (2.9) 17.3 % -0.36 [ -0.77, 0.05 ]
Total (95% CI) 265 258 100.0 % -0.55 [ -0.98, -0.12 ]
Heterogeneity: Tau2 = 0.23; Chi2 = 28.10, df = 5 (P = 0.00003); I2 =82%
Test for overall effect: Z = 2.52 (P = 0.012)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
Favours probiotic Favours placebo
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Analysis 1.2. Comparison 1 Probiotics versus placebo, Outcome 2 Change in pain frequency: 0 to 3 months’
postintervention. Sensitivity analysis.
Review: Dietary interventions for recurrent abdominal pain in childhood
Comparison: 1 Probiotics versus placebo
Outcome: 2 Change in pain frequency: 0 to 3 months’ postintervention. Sensitivity analysis
Study or subgroup Probiotic Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Francavilla 2010 67 1.1 (0.8) 69 2.2 (1.2) 27.0 % -1.07 [ -1.43, -0.71 ]
Gawronska 2007 52 2.2 (1.7) 52 2.6 (1.4) 26.1 % -0.25 [ -0.64, 0.13 ]
Romano 2010 30 2.12 (0.6) 26 2.6 (1.5) 21.5 % -0.43 [ -0.96, 0.11 ]
Weizman 2016 47 3.4 (2.6) 46 4.4 (2.9) 25.4 % -0.36 [ -0.77, 0.05 ]
Total (95% CI) 196 193 100.0 % -0.54 [ -0.94, -0.14 ]
Heterogeneity: Tau2 = 0.12; Chi2 = 11.24, df = 3 (P = 0.01); I2 =73%
Test for overall effect: Z = 2.62 (P = 0.0087)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
Favours probiotic Favours placebo
62Dietary interventions for recurrent abdominal pain in childhood (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.3. Comparison 1 Probiotics versus placebo, Outcome 3 Change in pain intensity: 0 to 3 months’
postintervention.
Review: Dietary interventions for recurrent abdominal pain in childhood
Comparison: 1 Probiotics versus placebo
Outcome: 3 Change in pain intensity: 0 to 3 months’ postintervention
Study or subgroup Probiotic Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Asgarshirazi 2015 29 3.93 (1.06) 25 4.24 (1.33) 13.2 % -0.26 [ -0.79, 0.28 ]
Eftekhari 2015 40 2.53 (1.43) 40 2.25 (1.46) 14.8 % 0.19 [ -0.25, 0.63 ]
Francavilla 2010 67 2.3 (1.3) 69 3.4 (2.1) 16.2 % -0.62 [ -0.97, -0.28 ]
Gawronska 2007 52 2.5 (1.9) 52 2.9 (1.5) 15.6 % -0.23 [ -0.62, 0.15 ]
Kianifar 2015 26 0.8 (0.9) 26 1.5 (0.8) 12.8 % -0.81 [ -1.38, -0.24 ]
Romano 2010 30 1.01 (0.6) 26 2.1 (0.8) 12.3 % -1.54 [ -2.14, -0.93 ]
Weizman 2016 47 4.8 (3.3) 46 6.4 (4.1) 15.2 % -0.43 [ -0.84, -0.02 ]
Total (95% CI) 291 284 100.0 % -0.50 [ -0.85, -0.15 ]
Heterogeneity: Tau2 = 0.17; Chi2 = 24.95, df = 6 (P = 0.00035); I2 =76%
Test for overall effect: Z = 2.80 (P = 0.0052)
Test for subgroup differences: Not applicable
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Analysis 1.4. Comparison 1 Probiotics versus placebo, Outcome 4 Change in pain intensity: 0 to 3 months’
postintervention. Sensitivity analysis.
Review: Dietary interventions for recurrent abdominal pain in childhood
Comparison: 1 Probiotics versus placebo
Outcome: 4 Change in pain intensity: 0 to 3 months’ postintervention. Sensitivity analysis
Study or subgroup Probiotic Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Francavilla 2010 67 2.3 (1.3) 69 3.4 (2.1) 23.1 % -0.62 [ -0.97, -0.28 ]
Gawronska 2007 52 2.5 (1.9) 52 2.9 (1.5) 22.0 % -0.23 [ -0.62, 0.15 ]
Kianifar 2015 26 0.8 (0.9) 26 1.5 (0.8) 17.3 % -0.81 [ -1.38, -0.24 ]
Romano 2010 30 1.01 (0.6) 26 2.1 (0.8) 16.4 % -1.54 [ -2.14, -0.93 ]
Weizman 2016 47 4.8 (3.3) 46 6.4 (4.1) 21.3 % -0.43 [ -0.84, -0.02 ]
Total (95% CI) 222 219 100.0 % -0.68 [ -1.05, -0.30 ]
Heterogeneity: Tau2 = 0.13; Chi2 = 14.00, df = 4 (P = 0.01); I2 =71%
Test for overall effect: Z = 3.56 (P = 0.00037)
Test for subgroup differences: Not applicable
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Analysis 1.5. Comparison 1 Probiotics versus placebo, Outcome 5 Improvement in pain: 0 to 3 months’
postintervention.
Review: Dietary interventions for recurrent abdominal pain in childhood
Comparison: 1 Probiotics versus placebo
Outcome: 5 Improvement in pain: 0 to 3 months’ postintervention
Study or subgroup Probiotic Placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bausserman 2005 11/25 10/25 9.7 % 1.18 [ 0.38, 3.63 ]
Eftekhari 2015 15/40 21/40 13.1 % 0.54 [ 0.22, 1.32 ]
Francavilla 2010 48/67 37/69 16.7 % 2.18 [ 1.07, 4.45 ]
Gawronska 2007 25/52 23/52 15.4 % 1.17 [ 0.54, 2.53 ]
Giannetti 2017 25/73 15/73 16.0 % 2.01 [ 0.96, 4.24 ]
Guandalini 2010 44/59 29/59 15.3 % 3.03 [ 1.40, 6.60 ]
Saneian 2015 27/45 17/43 13.8 % 2.29 [ 0.98, 5.39 ]
Total (95% CI) 361 361 100.0 % 1.63 [ 1.07, 2.47 ]
Total events: 195 (Probiotic), 152 (Placebo)
Heterogeneity: Tau2 = 0.14; Chi2 = 10.89, df = 6 (P = 0.09); I2 =45%
Test for overall effect: Z = 2.27 (P = 0.023)
Test for subgroup differences: Not applicable
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Analysis 1.6. Comparison 1 Probiotics versus placebo, Outcome 6 Improvement in pain: 0 to 3 months’
postintervention. Sensitivity analysis.
Review: Dietary interventions for recurrent abdominal pain in childhood
Comparison: 1 Probiotics versus placebo
Outcome: 6 Improvement in pain: 0 to 3 months’ postintervention. Sensitivity analysis
Study or subgroup Probiotic Placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bausserman 2005 11/25 10/25 8.5 % 1.18 [ 0.38, 3.63 ]
Francavilla 2010 48/67 37/69 21.3 % 2.18 [ 1.07, 4.45 ]
Gawronska 2007 25/52 23/52 18.1 % 1.17 [ 0.54, 2.53 ]
Giannetti 2017 25/73 15/73 19.4 % 2.01 [ 0.96, 4.24 ]
Guandalini 2010 44/59 29/59 17.9 % 3.03 [ 1.40, 6.60 ]
Saneian 2015 27/45 17/43 14.8 % 2.29 [ 0.98, 5.39 ]
Total (95% CI) 321 321 100.0 % 1.95 [ 1.40, 2.70 ]
Total events: 180 (Probiotic), 131 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.96, df = 5 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 3.97 (P = 0.000071)
Test for subgroup differences: Not applicable
0.2 0.5 1 2 5
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Analysis 1.7. Comparison 1 Probiotics versus placebo, Outcome 7 Improvement in pain: 0 to 3 months’
postintervention. Subgroup analysis (irritable bowel syndrome).
Review: Dietary interventions for recurrent abdominal pain in childhood
Comparison: 1 Probiotics versus placebo
Outcome: 7 Improvement in pain: 0 to 3 months’ postintervention. Subgroup analysis (irritable bowel syndrome)
Study or subgroup Probiotic Placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bausserman 2005 11/25 10/25 18.9 % 1.18 [ 0.38, 3.63 ]
Francavilla 2010 33/42 17/38 23.9 % 4.53 [ 1.71, 12.02 ]
Giannetti 2017 20/48 7/48 23.5 % 4.18 [ 1.56, 11.21 ]
Guandalini 2010 44/59 29/59 33.8 % 3.03 [ 1.40, 6.60 ]
Total (95% CI) 174 170 100.0 % 3.01 [ 1.77, 5.13 ]
Total events: 108 (Probiotic), 63 (Placebo)
Heterogeneity: Tau2 = 0.06; Chi2 = 3.77, df = 3 (P = 0.29); I2 =21%
Test for overall effect: Z = 4.06 (P = 0.000049)
Test for subgroup differences: Not applicable
0.2 0.5 1 2 5
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Analysis 1.8. Comparison 1 Probiotics versus placebo, Outcome 8 Improvement in pain: 3 to 6 months’
postintervention.
Review: Dietary interventions for recurrent abdominal pain in childhood
Comparison: 1 Probiotics versus placebo
Outcome: 8 Improvement in pain: 3 to 6 months’ postintervention
Study or subgroup Probiotic Placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Francavilla 2010 53/67 43/69 55.6 % 2.29 [ 1.07, 4.92 ]
Saneian 2015 29/45 23/43 44.4 % 1.58 [ 0.67, 3.71 ]
Total (95% CI) 112 112 100.0 % 1.94 [ 1.10, 3.43 ]
Total events: 82 (Probiotic), 66 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.41, df = 1 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 2.28 (P = 0.023)
Test for subgroup differences: Not applicable
0.2 0.5 1 2 5
Favours placebo Favours probiotic
Analysis 2.1. Comparison 2 Fibre versus placebo, Outcome 1 Change in pain intensity: 0 to 3 months’
postintervention.
Review: Dietary interventions for recurrent abdominal pain in childhood
Comparison: 2 Fibre versus placebo
Outcome: 1 Change in pain intensity: 0 to 3 months’ postintervention
Study or subgroup Fibre Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Romano 2013 30 1.63 (0.16) 30 2.05 (0.19) 49.4 % -2.36 [ -3.03, -1.69 ]
Shulman 2016 33 3.24 (1.58) 42 3.46 (1.55) 50.6 % -0.14 [ -0.60, 0.32 ]
Total (95% CI) 63 72 100.0 % -1.24 [ -3.41, 0.94 ]
Heterogeneity: Tau2 = 2.38; Chi2 = 28.91, df = 1 (P<0.00001); I2 =97%
Test for overall effect: Z = 1.11 (P = 0.27)
Test for subgroup differences: Not applicable
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Analysis 2.2. Comparison 2 Fibre versus placebo, Outcome 2 Improvement in pain: 0 to 3 months’
postintervention.
Review: Dietary interventions for recurrent abdominal pain in childhood
Comparison: 2 Fibre versus placebo
Outcome: 2 Improvement in pain: 0 to 3 months’ postintervention
Study or subgroup Fibre Placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Feldman 1985 13/26 7/26 35.5 % 2.71 [ 0.85, 8.64 ]
Horvath 2013 23/41 20/43 64.5 % 1.47 [ 0.62, 3.47 ]
Total (95% CI) 67 69 100.0 % 1.83 [ 0.92, 3.65 ]
Total events: 36 (Fibre), 27 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.69, df = 1 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 1.71 (P = 0.087)
Test for subgroup differences: Not applicable
0.2 0.5 1 2 5
Favours placebo Favours fibre
A D D I T I O N A L T A B L E S
Table 1. Assessment of risk of bias in included studies
Domain ’Risk of bias’ judgement
Low High Unclear
Selection bias Selection bias
Random sequence generation If the study details any of the
following methods: simple ran-
domisation (such as coin-toss-
ing, throwing dice, or dealing
previously shuffled cards, a list
of random numbers, or com-
If the study details no ran-
domisation or other inadequate
method such as alternation, as-
signment based ondate of birth,
case record number, and date of
presentation. These may be re-
If there is insufficient detail to
judge the risk of bias.
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Table 1. Assessment of risk of bias in included studies (Continued)
puter-generated random num-
bers) or restricted randomisa-
tion (blocked, ideally with vary-
ing block sizes or stratified
groups, provided that within-
groups randomisation is not af-
fected)
ferred to as ‘quasi-random’
Allocation concealment If the study details concealed al-
location sequence in sufficient
detail to determine that alloca-
tions could not have been fore-
seen in advance of or during en-
rolment
If the study details a method
where the allocation is known
prior to assignment
If there is insufficient detail to
judge the risk of bias.
Performance bias Performance bias
Blinding of participants and
personnel
If the study details a method
of blinding the participants and
personnel. This requires suffi-
cient detail to show they were
unable to identify the therapeu-
tic intervention from the con-
trol intervention
Considering the nature of the
interventions, it may not be
possible to blind the partici-
pants and therapists. The effect
of this will be addressed in the
Discussion
If there is insufficient detail to
judge the risk of bias.
Detection bias Detection bias
Blinding of outcome assess-
ment
If the study details a blinded
outcome assessment. This may
only be possible for outcomes
that are externally assessed
If the outcome assessment is not
blinded. We expect this may be
unavoidable for self rated out-
comes of unblinded interven-
tions
If there is insufficient detail to
judge the risk of bias.
Attrition bias Attrition bias
Incomplete outcome data If the study reports attrition
and exclusions, including the
numbers in each intervention
group (compared with total
randomised participants), rea-
sons for attrition or exclusions,
and any re-inclusions. Also, the
impact ofmissingdata is not be-
lieved to alter the conclusions,
and there are acceptable reasons
for the missing data
We may judge the risk of attri-
tion bias to be high due to the
amount, nature, or handling
(such as per-protocol analysis)
of incomplete outcome data
If there is insufficient detail to
judge the risk of bias, e.g. if the
number of people randomised
to each treatment is not re-
ported
Reporting bias Reporting bias
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Table 1. Assessment of risk of bias in included studies (Continued)
Selective outcome reporting If there is judged to be complete
reporting, which will be found
on comparison of the published
study and protocol, if available
If the reporting is selective, so
that some outcome data are not
reported
If there is insufficient detail to
judge the risk of bias, such as
the protocol is not available
Other sources of bias Other sources of
Assessment of other sources of
bias in other domains not cov-
ered by the tool, including
validity of outcome measures
utilised
If there is judged to be no other
factors that would be likely to
introduce major potential bias
If other factors are identified
that are judged to represent a
high risk of bias
If there is insufficient detail to
judge the risk of other bias
A P P E N D I C E S
Appendix 1. Search strategies
Cochrane Central Register of Controlled Trials (CENTRAL; 2016, Issue 5) in the Cochrane Library
Search dates: 19 April 2013 (990 records); 11 April 2014 (1271 records); 26 March 2015 (49 records); 10 June 2016 (81 records).
#1 Pain*:ti,ab
#2 Ache*:ti,ab
#3 Sore*:ti,ab
#4 Discomfort*:ti,ab
#5 Distress*:ti,ab
#6 Cramp*:ti,ab
#7 Disorder:ti,ab
#8 Disorders:ti,ab
#9 Symptom:ti,ab
#10 Symptoms:ti,ab
#11 Migraine:ti,ab
#12 Migraines:ti,ab
#13 Epilep*:ti,ab
#14 Colic*:ti,ab
#15 Syndrome:ti,ab
#16 Syndromes:ti,ab
#17 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16
#18 Stomach*:ti,ab
#19 Abdom*:ti,ab
#20 Intestin*:ti,ab
#21 Viscera*:ti,ab
#22 Tummy:ti,ab
#23 Bowel*:ti,ab
#24 Belly:ti,ab
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#25 Gastrointestinal:ti,ab
#26 GI:ti,ab
#27 Gastric:ti,ab
#28 #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27
#29 #17 and #28
#30 Colonic disease*:ti,ab
#31 Irritable bowel:ti,ab
#32 IBS:ti,ab
#33 Functional dyspepsia:ti,ab
#34 MeSH descriptor: [Irritable Bowel Syndrome] explode all trees
#35 MeSH descriptor: [Colonic Diseases, Functional] explode all trees
#36 MeSH descriptor: [Abdominal Pain] explode all trees
#37 MeSH descriptor: [Dyspepsia] explode all trees
#38 MeSH descriptor: [Colic] explode all trees
#39 MeSH descriptor: [Abdomen, Acute] explode all trees
#40 #29 or #30 or #31 or #32 or #33 or #34 or #35 or #36 or #37 or #38 or #39
#41 Recurr*:ti,ab
#42 Chronic*:ti,ab
#43 Intermittent*:ti,ab
#44 Episode*:ti,ab
#45 Bout:ti,ab
#46 Bouts:ti,ab
#47 Spasm*:ti,ab
#48 Transitory:ti,ab
#49 Transient:ti,ab
#50 Functional:ti,ab
#51 Continu*:ti,ab
#52 Paroxysmal:ti,ab
#53 Persistent:ti,ab
#54 Idiopathic:ti,ab
#55 Unspecifi*:ti,ab
#56 Non specifi*:ti,ab
#57 Nonspecific*:ti,ab
#58 Motility:ti,ab
#59 MeSH descriptor: [Recurrence] explode all trees
#60 #41 or #42 or #43 or #44 or #45 or #46 or #47 or #48 or #49 or #50 or #51 or #52 or #53 or #54 or #55 or #56 or #57 or #58
or #59
#61 #40 and #60
#62 irritable bowel syndrome*:ti,ab
#63 #61 or #62
#64 Child*:ti,ab
#65 Adolescen*:ti,ab
#66 Boy*:ti,ab
#67 Girl*:ti,ab
#68 teen*:ti,ab
#69 Schoolchild*:ti,ab
#70 Young adult*:ti,ab
#71 Youth*:ti,ab
#72 Pediatric*:ti,ab
#73 Paediatric*:ti,ab
#74 Student*:ti,ab
#75 Pupil*:ti,ab
#76 Juvenile*:ti,ab
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#77 Young person*:ti,ab
#78 MeSH descriptor: [Child] explode all trees
#79 MeSH descriptor: [Adolescent] explode all trees
#80 MeSH descriptor: [Young Adult] explode all trees
#81 MeSH descriptor: [Students] explode all trees
#82 #64 or #65 or #66 or #67 or #68 or #69 or #70 or #71 or #72 or #73 or #74 or #75 or #76 or #77 or #78 or #79 or #80 or #81
#83 #63 and #82
Ovid MEDLINE In-Process & Other Non-Indexed Citations and Ovid Medline (1946 to current)
Search dates: 11 April 2013 (6238 records); 11 April 2014 (5957 records); 25 March 2015 (223 records); 9 June 2016 (300 records).
1 stomach*.tw.
2 abdom*.tw.
3 intestin*.tw.
4 viscera*.tw.
5 tummy.tw.
6 bowel*.tw.
7 belly.tw.
8 gastrointestinal.tw.
9 gi.tw.
10 gastric.tw.
11 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10
12 pain*.tw.
13 Ache*.tw.
14 Sore*.tw.
15 Discomfort*.tw.
16 Distress*.tw.
17 Cramp*.tw.
18 Disorder$1.tw.
19 Symptom$1.tw.
20 Migraine$1.tw.
21 Epilep*.tw.
22 syndrome$1.tw.
23 colic*.tw.
24 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23
25 irritable bowel$.tw.
26 ibs.tw.
27 functional dyspepsia.tw.
28 25 or 26 or 27
29 ((stomach* or abdom* or intestin* or viscera* or tummy or bowel* or belly or gastrointestinal or gi or gastric) adj3 (pain* or Ache*
or Sore* or Discomfort* or Distress* or Cramp* or Disorder$1 or Symptom$1 or Migraine$1 or Epilep* or syndrome$1 or colic*)).tw.
30 exp Irritable Bowel Syndrome/
31 exp Colonic Diseases/
32 exp Abdominal Pain/
33 exp Dyspepsia/
34 exp Colic/
35 exp Abdomen, Acute/
36 30 or 31 or 32 or 33 or 34 or 35
37 28 or 29 or 36
38 Recurr*.tw.
39 Chronic*.tw.
40 Intermittent*.tw.
41 Bout$1.tw.
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42 spasm*.tw.
43 Transitory.tw.
44 Transient.tw.
45 Functional.tw.
46 Continu*.tw.
47 Paroxysmal.tw.
48 Persistent.tw.
49 Idiopathic.tw.
50 unspecifi*.tw.
51 Non specifi*.tw.
52 nonspecifi*.tw.
53 motility.tw.
54 episod*.tw.
55 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 or 50 or 51 or 52 or 53 or 54
56 exp Recurrence/
57 55 or 56
58 37 and 57
59 irritable bowel syndrome*.tw.
60 58 or 59
61 randomized controlled trial.pt.
62 controlled clinical trial.pt.
63 randomi#ed.ab.
64 placebo$.ab.
65 randomly.ab.
66 trial.ab.
67 groups.ab.
68 exp animals/ not humans.sh.
69 or/61-67
70 69 not 68
71 60 and 70
72 exp Child/
73 exp Adolescent/
74 exp Young Adult/
75 exp Students/
76 Child*.tw.
77 Adolescen*.tw.
78 Young person*.tw.
79 Boy*.tw.
80 Girl*.tw.
81 teen*.tw.
82 Schoolchild*.tw.
83 Young adult*.tw.
84 Youth*.tw.
85 P*ediatric*.tw.
86 Student*.tw.
87 Pupil*.tw.
88 Juvenile*.tw.
89 72 or 73 or 74 or 75 or 76 or 77 or 78 or 79 or 80 or 81 or 82 or 83 or 84 or 85 or 86 or 87 or 88
90 71 and 89
Embase Ovid (1974 to current)
Search dates: 11 April 2013 (2272 records); 11 April 2014 (2523 records); 25 March 2015 (250 records); 9 June 2016 (345 records).
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1 recurr*.tw.
2 chronic*.tw.
3 intermittent*.tw.
4 bout$1.tw.
5 spasm*.tw.
6 transitory.tw.
7 transient.tw.
8 functional.tw.
9 continu*.tw.
10 paroxysmal.tw.
11 persistent.tw.
12 idiopathic.tw.
13 unspecifi*.tw.
14 non specifi*.tw.
15 nonspecifi*.tw.
16 motility.tw.
17 episod*.tw.
18 or/1-17
19 exp recurrent disease/
20 18 or 19
21 stomach*.tw.
22 abdom*.tw.
23 intestin*.tw.
24 viscera*.tw.
25 tummy.tw.
26 bowel*.tw.
27 belly.tw.
28 gastrointestinal.tw.
29 gi.tw.
30 gastric.tw.
31 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30
32 pain*.tw.
33 Ache*.tw.
34 Sore*.tw.
35 Discomfort*.tw.
36 Distress*.tw.
37 Cramp*.tw.
38 Disorder$1.tw.
39 Symptom$1.tw.
40 Migraine$1.tw.
41 Epilep*.tw.
42 syndrome$1.tw.
43 colic*.tw.
44 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43
45 irritable bowel$.tw.
46 ibs.tw.
47 functional dyspepsia.tw.
48 45 or 46 or 47
49 ((stomach* or abdom* or intestin* or viscera* or tummy or bowel* or belly or gastrointestinal or gi or gastric) adj3 (pain* or Ache*
or Sore* or Discomfort* or Distress* or Cramp* or Disorder$1 or Symptom$1 or Migraine$1 or Epilep* or syndrome$1 or colic*)).tw.
50 48 or 49
51 exp colic/
52 exp irritable colon/
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53 exp abdominal pain/
54 exp dyspepsia/
55 colon disease/
56 50 or 51 or 52 or 53 or 54 or 55
57 20 and 56
58 irritable bowel syndrome*.tw.
59 57 or 58
60 Clinical trial/
61 Randomized controlled trial/
62 Randomization/
63 Single blind procedure/
64 Double blind procedure/
65 Crossover procedure/
66 Placebo/
67 Randomi?ed controlled trial$.tw.
68 Rct.tw.
69 Random allocation.tw.
70 Randomly allocated.tw.
71 Allocated randomly.tw.
72 (allocated adj2 random).tw.
73 Single blind$.tw.
74 Double blind$.tw.
75 ((treble or triple) adj blind$).tw.
76 Placebo$.tw.
77 Prospective study/
78 or/60-77
79 Case study/
80 Case report.tw.
81 Abstract report/ or letter/
82 or/79-81
83 78 not 82
84 59 and 83
85 exp Child/
86 exp Adolescent/
87 exp Young Adult/
88 exp Students/
89 Child*.tw.
90 Adolescen*.tw.
91 Young person*.tw.
92 Boy*.tw.
93 Girl*.tw.
94 teen*.tw.
95 Schoolchild*.tw.
96 Young adult*.tw.
97 Youth*.tw.
98 P*ediatric*.tw.
99 Student*.tw.
100 Pupil*.tw.
101 Juvenile*.tw.
102 85 or 86 or 87 or 88 or 89 or 90 or 91 or 92 or 93 or 94 or 95 or 96 or 97 or 98 or 99 or 100 or 101
103 84 and 102
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CINAHL Healthcare Databases Advanced Search (Cumulative Index to Nursing and Allied Health Literature;
1981 to current)
Search dates: 18 April 2013 (175 records); 11 April 2014 (195 records); 26 March 2015 (21 records); 9 June 2016 (11 records).
1. CINAHL; recurr*.ti,ab;
2. CINAHL; chronic*.ti,ab;
3. CINAHL; intermittent*.ti,ab;
4. CINAHL; (bout OR bouts).ti,ab;
5. CINAHL; spasm*.ti,ab;
6. CINAHL; transitory.ti,ab;
7. CINAHL; transient.ti,ab;
8. CINAHL; functional.ti,ab;
9. CINAHL; continu*.ti,ab;
10. CINAHL; paroxysmal.ti,ab;
11. CINAHL; persistent.ti,ab;
12. CINAHL; idiopathic.ti,ab;
13. CINAHL; unspecifi*.ti,ab;
14. CINAHL; “non specifi*”.ti,ab;
15. CINAHL; nonspecifi*.ti,ab;
16. CINAHL; motility.ti,ab;
17. CINAHL; episod*.ti,ab;
18. CINAHL; exp RECURRENCE/;
19. CINAHL; 1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9 OR 10 OR 11 OR 12 OR 13 OR 14 OR 15 OR 16 OR 17 OR 18;
20. CINAHL; stomach*.ti,ab;
21. CINAHL; abdom*.ti,ab;
22. CINAHL; intestin*.ti,ab;
23. CINAHL; viscera*.ti,ab;
24. CINAHL; tummy.ti,ab;
25. CINAHL; bowel*.ti,ab;
26. CINAHL; belly.ti,ab;
27. CINAHL; gastrointestinal.ti,ab;
28. CINAHL; gi.ti,ab;
29. CINAHL; gastric.ti,ab;
30. CINAHL; 20 OR 21 OR 22 OR 23 OR 24 OR 25 OR 26 OR 27 OR 28 OR 29;
31. CINAHL; pain*.ti,ab;
32. CINAHL; Ache*.ti,ab;
33. CINAHL; Sore*.ti,ab;
34. CINAHL; Discomfort*.ti,ab;
35. CINAHL; Distress*.ti,ab;
36. CINAHL; Cramp*.ti,ab;
37. CINAHL; (Disorder OR Disorders).ti,ab;
38. CINAHL; (Symptom OR Symptoms).ti,ab;
39. CINAHL; (Migraine OR Migraines).ti,ab;.
40. CINAHL; Epilep*.ti,ab;
41. CINAHL; (syndrome OR syndromes).ti,ab;
42. CINAHL; colic*.ti,ab;
43. CINAHL; 31 OR 32 OR 33 OR 34 OR 35 OR 36 OR 37 OR 38 OR 39 OR 40 OR 41 OR 42;
44. CINAHL; 30 AND 43;
45. CINAHL; “irritable bowel*”.ti,ab;
46. CINAHL; ibs.ti,ab;
47. CINAHL; “functional dyspepsia”.ti,ab;
48. CINAHL; exp COLIC/;
49. CINAHL; exp IRRITABLE BOWEL SYNDROME/;
77Dietary interventions for recurrent abdominal pain in childhood (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
50. CINAHL; exp COLONIC DISEASES, FUNCTIONAL/;
51. CINAHL; exp ABDOMINAL PAIN/;
52. CINAHL; exp DYSPEPSIA/;
53. CINAHL; 45 OR 46 OR 47 OR 48 OR 49 OR 50 OR 51 OR 52;
54. CINAHL; 44 OR 53;
55. CINAHL; 19 AND 54;
56. CINAHL; (irritable AND bowel AND syndrome*).ti,ab;
57. CINAHL; 55 OR 56;
58. CINAHL; Child*.ti,ab;
59. CINAHL; Adolescen*.ti,ab;
60. CINAHL; “Young person*”.ti,ab;
61. CINAHL; Boy*.ti,ab;
62. CINAHL; Girl*.ti,ab;
63. CINAHL; teen*.ti,ab;
64. CINAHL; Schoolchild*.ti,ab;
65. CINAHL; “Young adult*”.ti,ab;
66. CINAHL; Youth*.ti,ab;
67. CINAHL; Student*.ti,ab;
68. CINAHL; Pupil*.ti,ab;
69. CINAHL; Juvenile*.ti,ab;
70. CINAHL; exp CHILD/;
71. CINAHL; exp STUDENTS/;
72. CINAHL; 70 OR 71;
73. CINAHL; Pediatric*.ti,ab;
74. CINAHL; Paediatric*.ti,ab;
75. CINAHL; 67 OR 68 OR 69 OR 72 OR 73 OR 74;
76. CINAHL; 63 OR 64 OR 65 OR 66;
77. CINAHL; 58 OR 59 OR 60 OR 61 OR 62;
78. CINAHL; 70 OR 73 OR 74 OR 75;
79. CINAHL; 57 AND 78;
80. CINAHL; exp RANDOMIZED CONTROLLED TRIALS/;
81. CINAHL; random*.ti,ab;
82. CINAHL; “clin* trial*”.ti,ab;
83. CINAHL; (singl* OR doubl* OR tripl* OR trebl*).ti,ab;
84. CINAHL; (mask* OR blind*).ti,ab;
85. CINAHL; 83 AND 84;
86. CINAHL; “random* allocate*”.ti,ab;
87. CINAHL; “random assign*”.ti,ab;
88. CINAHL; exp RANDOM ASSIGNMENT/;
89. CINAHL; exp CLINICAL TRIALS/;
90. CINAHL; exp META ANALYSIS/;
91. CINAHL; 88 OR 89 OR 90;
92. CINAHL; 80 OR 81 OR 82 OR 85 OR 86 OR 87;
93. CINAHL; 91 OR 92;
94. CINAHL; 79 AND 93;
PsycINFO Ovid (1806 to current)
Search dates: 18 April 2013 ( 238 records); 11 April 2014 (757 records); 25 March 2015 (47 records); 9 June 2016 (87 records).
1 stomach*.tw.
2 abdom*.tw.
3 intestin*.tw.
4 viscera*.tw.
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5 tummy.tw.
6 bowel*.tw.
7 belly.tw.
8 gastrointestinal.tw.
9 gi.tw.
10 gastric.tw.
11 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10
12 pain*.tw.
13 Ache*.tw.
14 Sore*.tw.
15 Discomfort*.tw.
16 Distress*.tw.
17 Cramp*.tw.
18 Disorder$1.tw.
19 Symptom$1.tw.
20 Migraine$1.tw.
21 Epilep*.tw.
22 syndrome$1.tw.
23 colic*.tw.
24 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23
25 irritable bowel$.tw.
26 ibs.tw.
27 functional dyspepsia.tw.
28 25 or 26 or 27
29 ((stomach* or abdom* or intestin* or viscera* or tummy or bowel* or belly or gastrointestinal or gi or gastric) adj3 (pain* or Ache*
or Sore* or Discomfort* or Distress* or Cramp* or Disorder$1 or Symptom$1 or Migraine$1 or Epilep* or syndrome$1 or colic*)).tw.
30 exp Irritable Bowel Syndrome/
31 exp Dyspepsia/
32 recurr*.tw.
33 chronic*.tw.
34 intermittent*.tw.
35 bout$1.tw.
36 spasm*.tw.
37 transitory.tw.
38 transient.tw.
39 functional.tw.
40 continu*.tw.
41 paroxysmal.tw.
42 persistent.tw.
43 idiopathic.tw.
44 unspecifi*.tw.
45 non specifi*.tw.
46 nonspecifi*.tw.
47 motility.tw.
48 episod*.tw.
49 or/32-48
50 irritable bowel syndrome*.tw.
51 exp Students/
52 Child*.tw.
53 Adolescen*.tw.
54 Young person*.tw.
55 Boy*.tw.
56 Girl*.tw.
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57 teen*.tw.
58 Schoolchild*.tw.
59 Young adult*.tw.
60 Youth*.tw.
61 P*ediatric*.tw.
62 Student*.tw.
63 Pupil*.tw.
64 Juvenile*.tw.
65 28 or 29 or 30 or 31
66 49 and 65
67 50 or 66
68 51 or 52 or 53 or 54 or 55 or 56 or 57 or 58 or 59 or 60 or 61 or 62 or 63 or 64
69 67 and 68
ERIC ProQuest (Education Resources Information Center; 1966 to current)
Search dates: 19 April 2013 (276 records); 11 April 2014 (294 records); 26 March 2015 (no records); 9 June 2016 (2 records).
(ab,ti(Pain*) OR ab,ti(Ache*) OR ab,ti(Sore*) OR ab,ti(Discomfort*) OR ab,ti(Distress*) OR ab,ti(Cramp*) OR ab,ti(Disorder) OR
ab,ti(Disorders) OR ab,ti(Symptom*) OR ab,ti(Migraine*) OR ab,ti(Epilep*) OR ab,ti(Colic*) OR ab,ti(Syndrome*))
AND
(Ab,ti(Recurr*) OR ab,ti(Chronic*) OR ab,ti(Intermittent*) OR ab,ti(Episode*) OR ab,ti(Bout) OR ab,ti(Bouts) OR ab,ti((Spasm*)
OR ab,ti(Transitory) OR ab,ti(Transient) OR ab,ti(Functional) OR ab,ti(Continu*) OR ab,ti(paroxysmal) OR ab,ti(Persistent) OR
ab,ti (Idiopathic) OR ab,ti(Unspecifi*) OR ab,ti(Non specifi*) OR ab,ti(motility) OR SU.EXACT.EXPLODE(“Recurrence”))
AND
(Ab,ti(Stomach*) OR ab,ti(Abdom*) OR ab,ti(Sore*) OR ab,ti(Intestin*) OR ab,ti(Viscera*) OR ab,ti(Tummy) OR ab,ti(Bowel*) OR
ab,ti(Belly) OR ab,ti(Gastrointestinal) OR ab,ti(GI) OR ab,ti(Epilep*) OR ab,ti(Gastric))
OR
(Ab,ti(irritable bowel*) OR ab,ti(ibs) OR ab,ti(colonic disease*) OR ab,ti(functional dyspepsia))
British Education Index ProQuest (1975 to current)
Search dates: 19 April 2013 (46 records); 11 April 2014 (48 records); 26 March 2015 (no records); 9 June 2016 (5 records).
((ab,ti(Stomach*) OR ab,ti(Abdom*) OR ab,ti(Intestin*) OR ab,ti(Viscera*) OR ab,ti(Tummy) OR ab,ti(Bowel*) OR ab,ti(Belly) OR
ab,ti(Gastrointestinal) OR ab,ti(GI) OR ab,ti(Gastric))
AND
((ab,ti(Pain*) OR ab,ti(Ache*) OR ab,ti(Sore*) OR ab,ti(Discomfort*) OR ab,ti(Distress*) OR ab,ti(Cramp*) OR ab,ti(Disorder)
OR ab,ti(Disorders) OR ab,ti(Symptom) OR OR ab,ti(Symptoms) OR ab,ti(Migraine) OR ab,ti(Migraines) OR ab,ti(Epilep*) OR
ab,ti(Colic*) OR ab,ti(Syndrome) OR ab,ti(Syndromes))
OR
(Ab,ti(irritable bowel*) OR ab,ti(ibs) OR ab,ti(Functional dyspepsia))
ASSIA (Applied Social Sciences Index and Abstracts ProQuest; 1987 to current)
Search dates: 19 April 2013 (179 records); 11 April 2014 (545 records); 26 March 2015 (27 records); 9 June 2016 (48 records).
((ab,ti(Stomach*) OR ab,ti(Abdom*) OR ab,ti(Intestin*) OR ab,ti(Viscera*) OR ab,ti(Tummy) OR ab,ti(Bowel*) OR ab,ti(Belly) OR
ab,ti(Gastrointestinal) OR ab,ti(GI) OR ab,ti(gastric)
AND
(ab,ti(Pain*) OR ab,ti(Ache*) OR ab,ti(Sore*) OR ab,ti(Discomfort*) OR ab,ti(Distress*) OR ab,ti(Cramp*) OR ab,ti(Disorder)
OR ab,ti(Disorders) OR ab,ti(Symptom*) OR ab,ti(Symptoms) OR ab,ti(Migraine*) OR ab,ti(Epilep*) OR ab,ti(Syndrome) OR
ab,ti(Syndromes) OR ab,ti(colic*)
AND
(ab,ti(Recurr*) OR ab,ti(Chronic*) OR ab,ti(Intermittent*) OR ab,ti(Episode*) OR ab,ti(Bout) OR ab,ti(bouts) OR ab,ti(Spasm*)
OR ab,ti(Transitory) OR ab,ti(Transient) OR ab,ti(Functional) OR ab,ti(Continu*) OR ab,ti(Paroxysmal) OR ab,ti(Persistent) OR
ab,ti(Idiopathic) OR ab,ti(Unspecifi*) OR ab,ti(Non specifi*) OR ab,ti(motility))
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OR
(ab,ti(irritable bowel) OR ab,ti(ibs) OR ab,ti(functional dyspepsia))
Allied and Complementary Medicine Healthcare Databases Advanced Search (AMED; 1985 to current)
Search dates: 18 April 2013 (63 records); 11 April 2014 (74 records); 25 March 2015 (1 record); 9 June 2016 (1 record).
1. AMED; Recurr*.ti,ab;
2. AMED; Chronic*.ti,ab;
3. AMED; Intermittent*.ti,ab;
4. AMED; Episod*.ti,ab;
5. AMED; (Bout OR Bouts).ti,ab;
6. AMED; Spasm*.ti,ab;
7. AMED; Transitory.ti,ab;
8. AMED; Transient.ti,ab;
9. AMED; Functional.ti,ab;
10. AMED; Continu*.ti,ab;
11. AMED; Paroxysmal.ti,ab;
12. AMED; Persistent.ti,ab;
13. AMED; Idiopathic.ti,ab;
14. AMED; Unspecifi*.ti,ab;
15. AMED; “Non specifi*”.ti,ab;
16. AMED; Nonspecific*.ti,ab;
17. AMED; Motility.ti,ab;
18. AMED; exp RECURRENCE/;
19. AMED; 1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9 OR 10 OR 11 OR 12 OR 13 OR 14 OR 15 OR 16 OR 17 OR 18;.
20. AMED; Pain*.ti,ab;
21. AMED; Ache*.ti,ab;
22. AMED; Sore*.ti,ab;
23. AMED; Discomfort*.ti,ab;
24. AMED; Distress*.ti,ab;
25. AMED; Cramp*.ti,ab;
26. AMED; (Disorder OR Disorders).ti,ab;
27. AMED; (Symptom OR Symptoms).ti,ab;
28. AMED; (Migraine OR Migraines).ti,ab;
29. AMED; Epilep*.ti,ab;
30. AMED; Colic*.ti,ab;
31. AMED; (Syndrome OR Syndromes).ti,ab;
32. AMED; 20 OR 21 OR 22 OR 23 OR 24 OR 25 OR 26 OR 27 OR 28 OR 29 OR 30 OR 31;
33. AMED; Stomach*.ti,ab;
34. AMED; Abdom*.ti,ab;
35. AMED; Intestin*.ti,ab;
36. AMED; Viscera*.ti,ab;
37. AMED; Tummy.ti,ab;
38. AMED; Bowel*.ti,ab;
39. AMED; Belly.ti,ab;
40. AMED; Gastrointestinal.ti,ab;
41. AMED; GI.ti,ab;
42. AMED; Gastric.ti,ab;
43. AMED; 33 OR 34 OR 35 OR 36 OR 37 OR 38 OR 39 OR 40 OR 41 OR 42;
44. AMED; 32 AND 43;
45. AMED; “Colonic disease*”.ti,ab;
46. AMED; “Irritable bowel”.ti,ab;
47. AMED; IBS.ti,ab; 86
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48. AMED; “Functional dyspepsia”.ti,ab;
49. AMED; exp IRRITABLE BOWEL SYNDROME/;
50. AMED; exp COLONIC DISEASE/;
51. AMED; exp ABDOMINAL PAIN/;
52. AMED; exp DYSPEPSIA/;
53. AMED; 45 OR 46 OR 47 OR 48 OR 49 OR 50 OR 51 OR 52;
54. AMED; 44 OR 53;
55. AMED; 19 AND 54;
56. AMED; (irritable AND bowel AND syndrome*).ti,ab;
57. AMED; Child*.ti,ab;
58. AMED; Adolescen*.ti,ab;
59. AMED; Boy*.ti,ab;
60. AMED; Girl*.ti,ab;
61. AMED; teen*.ti,ab;
62. AMED; Schoolchild*.ti,ab;
63. AMED; “Young adult*”.ti,ab;
64. AMED; Youth*.ti,ab; 767 results.
65. AMED; (Pediatric* OR Paediatric*).ti,ab;
66. AMED; Student*.ti,ab;
67. AMED; Pupil*.ti,ab;
68. AMED; Juvenile*.ti,ab;
69. AMED; “Young person*”.ti,ab;
70. AMED; exp CHILD/;
71. AMED; exp ADOLESCENT/;
72. AMED; exp STUDENTS/;
73. AMED; 57 OR 58 OR 59 OR 60 OR 61 OR 62 OR 63 OR 64 OR 65 OR 66 OR 67 OR 68 OR 69 OR 70 OR 71 OR 72;
74 AMED; 55 OR 56;
75. AMED; 74 AND 73;
LILACS (Latin American and Caribbean Health Science Information database; lilacs.bvsalud.org/en/)
Search dates: 19 April 2013 (11 records); 11 April 2014 (13 records); 26 March 2015 (no records); 9 June 2016 (no records).
((Pt randomized controlled trial OR Pt controlled clinical trial ORMh randomized controlled trials ORMh random allocation ORMh
double-blind method OR Mh single-blind method) AND NOT (Ct animal AND NOT (Ct human and Ct animal)) OR (Pt clinical
trial OR Ex E05.318.760.535$ OR (Tw clin$ AND (Tw trial$ OR Tw ensa$ OR Tw estud$ ORTw experim$ OR Tw investiga$)) OR
((Tw singl$ OR Tw simple$ OR Tw doubl$ OR Tw doble$ OR Tw duplo$ OR Tw trebl$ OR Tw trip$) (trial$ OR ensa$ OR estud$
OR experim$ OR investiga$ OR singl$ OR simple$ OR Tw doubl$ OR Tw doble$ OR Tw duplo$ OR Tw trebl$ OR Tw trip$) AND
(Tw blind$ OR Tw cego$ OR Tw ciego$ OR Tw mask$ OR Tw mascar$)) OR Mh placebos OR Tw placebo$ OR (Tw random$ OR
Tw randon$ OR Tw casual$ OR Tw acaso$ OR Tw azar OR Tw aleator$) OR Mh research design) AND NOT (Ct animal AND
NOT (Ct human and Ct animal)) OR (Ct comparative study OR Ex E05.337$ ORMh follow-up studies ORMh prospective studies
OR Tw control$ OR Tw prospectiv$ OR Tw volunt$ OR Tw volunteer$) AND NOT (Ct animal AND NOT (Ct human and Ct
animal))) [Palavras]
and ((recurr$ or chronic$ or intermittent$ or bout or bouts or spasm$ or transitory or transient or functional or continu$ or Paroxysmal
or Persistent or Idiopathic or unspecifi$ or Non specifi$ or nonspecific$ or motility or episode$) [Palavras] and (pain$ or ache$ or sore$
or discomfort$ or distress$ cramp$ or colic$ or disorder or disorders or symptom or symptoms or Migraine$ or Epilep* or syndrome$)
and (stomach$ or abdom$ or intestin$ or viscera$ or tummy$ or bowel$ or belly or gastrointestinal or gi or gastric)) [Palavras]
OpenGrey (www.opengrey.eu)
Search dates : 19 April 2013 (1 record); 11 April 2014 (1 record); 26 March 2015 (no records); 9 June 2016 (no records).
Irritable bowel syndrom*
Ibs
functional dyspepsia
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Chronic* AND (abdom* OR stomach* OR intestin* OR viscera* OR tummy OR bowel* OR belly or gastrointestinal OR gi OR
gastric))
Recurr* AND (abdom*OR stomach*OR intestin* OR viscera* OR tummyORbowel* OR belly or gastrointestinal OR gi OR gastric))
Intermittent* AND (abdom* OR stomach* OR intestin* OR viscera* OR tummy OR bowel* OR belly or gastrointestinal OR gi OR
gastric))
Bout* AND (abdom* OR stomach* OR intestin* OR viscera* OR tummy OR bowel* OR belly or gastrointestinal OR gi OR gastric))
spasm* AND (abdom* OR stomach* OR intestin* OR viscera* OR tummyOR bowel* OR belly or gastrointestinal OR gi OR gastric))
Transitory AND (abdom* OR stomach* OR intestin* OR viscera* OR tummy OR bowel* OR belly or gastrointestinal OR gi OR
gastric))
Transient AND (abdom* OR stomach* OR intestin* OR viscera* OR tummy OR bowel* OR belly or gastrointestinal OR gi OR
gastric))
Functional AND (abdom* OR stomach* OR intestin* OR viscera* OR tummy OR bowel* OR belly or gastrointestinal OR gi OR
gastric))
Continu* AND (abdom* OR stomach* OR intestin* OR viscera* OR tummy OR bowel* OR belly or gastrointestinal OR gi OR
gastric))
Paroxysmal AND (abdom* OR stomach* OR intestin* OR viscera* OR tummy OR bowel* OR belly or gastrointestinal OR gi OR
gastric))
Persistent AND (abdom* OR stomach* OR intestin* OR viscera* OR tummy OR bowel* OR belly or gastrointestinal OR gi OR
gastric))
Idiopathic AND (abdom* OR stomach* OR intestin* OR viscera* OR tummy OR bowel* OR belly or gastrointestinal OR gi OR
gastric))
unspecifi* AND (abdom* OR stomach* OR intestin* OR viscera* OR tummy OR bowel* OR belly or gastrointestinal OR gi OR
gastric))
Non specifi* AND (abdom* OR stomach* OR intestin* OR viscera* OR tummy OR bowel* OR belly or gastrointestinal OR gi OR
gastric))
nonspecifi* AND (abdom* OR stomach* OR intestin* OR viscera* OR tummy OR bowel* OR belly or gastrointestinal OR gi OR
gastric))
motility AND (abdom* OR stomach* OR intestin* OR viscera* OR tummy OR bowel* OR belly or gastrointestinal OR gi OR
gastric))
episod* AND (abdom* OR stomach* OR intestin* OR viscera* OR tummyOR bowel* OR belly or gastrointestinal OR gi OR gastric))
ClinicalTrials.gov (clinicaltrials.gov/)
Search dates: 11 April 2014 (69 records); 26 March 2015 (35 records); 9 June 2016 (62 records).
“irritable bowel” OR “abdominal pain” in the condition field. Limited to children.
World Health Organization International Clinical Trials Registry Platform (WHO ICTRP;
apps.who.int/trialsearch)
Search dates: 11 April 2014 (106 records); 26 March 2015 (4 records); 9 June 2016 (32 records).
“irritable bowel” OR “abdominal pain” in the condition field. Limited to children and interventional studies.
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Appendix 2. Additional methods
The table below provides details of analyses that had been planned and described in the protocol (Martin 2014b), but were not employed
as they were not required.
Method planned for data analysis Reason for non-use
Unit of analysis issues Cluster-randomised trials
Cluster-randomised trials randomise
groups of people rather than individuals.
For each cluster-randomised trial, we will
first determine whether or not the data in-
corporates sufficient controls for clustering
(such as robust standard errors or hierar-
chical linear models). If data do not have
proper controls, wewill then attempt to ob-
tain an appropriate estimate of the data’s in-
tracluster correlation coefficient. If we can-
not find an estimate in the report of the
trial, then we will request an estimate from
the trial report authors. If the authors do
not provide an estimate, if possible, we will
obtain one from a similar study and con-
duct a sensitivity analysis to determine if
the results are robust when different values
are imputed. We will do this according to
procedures described in Higgins 2011b.
No cluster-randomised trials of dietary in-
terventions were located
Trials with multiple intervention groups
This is a common scenario. To avoid any
unit of analysis errors in the meta-analysis,
we will use the following approach for a
study that could contribute multiple com-
parisons
1. The interventions will only be
analysed together if they are clinically
similar. In this situation, the control
group will not be split, but the
intervention groups will be combined to
enable a single pair-wise comparison for
the meta-analysis. If the interventions are
similar enough to be in a single meta-
analysis but not able to be combined, then
the control group will be split. If the
interventions are not similar, the data will
be used in separate meta-analyses.
No multiple intervention group trials were
located.
Assessment of reporting biases Publication bias
If we identify sufficient trials (at least 10)
, we will use the outcome data to produce
a funnel plot to investigate the likelihood
We did not identify 10 or more trials for
any single outcome within any particular
type of dietary intervention
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(Continued)
of overt publication bias (Sutton 2000).
Any asymmetry of the funnel plot may in-
dicate possible publication bias. We will
explore other reasons for asymmetry such
as poor methodological quality or hetero-
geneity. We will look for publication bias
by comparing the results of the published
and unpublished data
Subgroup analysis and investigation of
heterogeneity
Wewill undertake subgroup analysis by the
duration of follow-up: immediate outcome
measurement (less than three months),
medium term (three to 12 months), and
long term (greater than 12 months)
We were able to perform analyses for im-
mediate outcome measurement. However,
due to a lack of trials reporting longer dura-
tions of follow-up, we could only perform
one analysis at medium-term follow-up
Sensitivity analyses Where data allow, we will perform sensitiv-
ity analyses to assess the robustness of con-
clusions in relation to two aspects of study
design:
1. the effect of inadequate allocation
concealment, by the removal of studies
judged as high or unclear risk of bias for
this domain; and
2. the effect of inadequate blinding to
treatment allocation by outcome assessors,
by the removal of studies judged as high
or unclear risk of bias for this domain.
We were only able to perform sensitivity
analyses for three probiotic intervention
outcomes. There were insufficient data to
perform any sensitivity analyses for fibre-
based intervention outcomes
WH A T ’ S N E W
Last assessed as up-to-date: 9 June 2016.
Date Event Description
12 December 2016 New citation required and conclusions have changed The inclusion of 15 new studies changed the conclu-
sions from those of the previous 2009 review, which
found no evidence to support any intervention. We
found moderate-quality evidence to support the use of
probiotics in recurrent abdominal pain
12 December 2016 New search has been performed Updated following a new search in April 2013 and
updated searches in April 2014,March 2015, and June
2016
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C O N T R I B U T I O N S O F A U T H O R S
Review design: AEM, SL
Review co-ordination: AEM
Data collection:
• Search strategy design: AEM, AB
• Searches: AEM, AB
• Search results screening: TVN, AEM, RAA, AB, RW. JTC resolved disagreements.
• Retrieval of papers: AEM, AB
• Paper screening and appraisal, and extraction of data: TVN, AEM, RAA, AB, JTC, RW
• Writing to authors for additional information: TVN, AEM, AB, RW
• Entering the data into Review Manager 5: TVN, AEM, RAA, AB, JTC
Analysis of the data: TVN, AEM, RAA, AB, JTC, SL
Interpretation of the data: TVN, AEM, RAA, SL
• Methodological perspective: TVN, AEM, RAA, AB, JTC, RW
• Clinical perspective: TVN, AEM, SL
D E C L A R A T I O N S O F I N T E R E S T
The work of the evidence synthesis team is funded by the National Institute for Health Research Collaboration for Leadership in
Applied Health Research and Care South West Peninsula (PenCLAHRC). However, the Funder had no role in the review itself.
Tamsin V Newlove-Delgado: none known.
Alice E Martin: none known.
Rebecca A Abbott: none known.
Alison Bethel: none known.
Joanna Thompson-Coon: none known.
Rebecca Whear: none known
Stuart Logan: none known.
The authors who practice clinical paediatrics are Alice E Martin and Stuart Logan. Alice is a Paediatric Trainee and works under
the guidance of various Consultant Paediatricians. Stuart is a Consultant Paediatrician and treats children according to current best
evidence, in light of their preference. There are therefore no conflicts of interest with this review.
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S O U R C E S O F S U P P O R T
Internal sources
• None, Other.
External sources
• None, Other.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Rebecca Whear was added to the review team after registration of the protocol (Martin 2014b). She was involved in screening abstracts
and full texts, data extraction, writing to authors, and contributed to discussions pertaining to methods.
Due to the varying definitions of duration of follow-up used in some studies, we classified when outcomes were measured into three
groups: postintervention (immediately or the earliest data available following the end of treatment), medium-term follow-up (three
to six months’ postintervention), and long-term follow-up (six months or longer). This is a slight change from the protocol (Martin
2014b), in which we planned to use four groups: immediate outcome measurement, short term (less than three months), medium term
(three to 12 months), and long term (greater than 12 months).
We reported adverse effects, in line with advice in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011c).
As requested by the editors, we also reported Tau² when using the random-effects model, which provides an estimate of the between-
study variance.
N O T E S
This is a new review, which supersedes a previously published review (Huertas-Ceballos 2009).
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